WO2023220081A1 - Systems and methods for small molecule encapsulation - Google Patents
Systems and methods for small molecule encapsulation Download PDFInfo
- Publication number
- WO2023220081A1 WO2023220081A1 PCT/US2023/021578 US2023021578W WO2023220081A1 WO 2023220081 A1 WO2023220081 A1 WO 2023220081A1 US 2023021578 W US2023021578 W US 2023021578W WO 2023220081 A1 WO2023220081 A1 WO 2023220081A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- plant
- composition
- phytochemicals
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/14—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/14—Vegetable proteins
- A23J3/16—Vegetable proteins from soybean
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/577—Malvaceae (Mallow family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/20—Ingredients acting on or related to the structure
- A23V2200/224—Encapsulating agent
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/20—Ingredients acting on or related to the structure
- A23V2200/25—Nanoparticles, nanostructures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
Definitions
- a method of encapsulating a plurality of small molecules comprising: obtaining plant-derived protein and one or more phytochemicals; mixing the plant- derived protein and the one or more phytochemicals with the plurality of small molecules in water to produce a mixture comprising a plurality of particles comprising a plurality of encapsulated small molecules.
- the plurality of small molecules can comprise a plurality of ketone molecules.
- the plurality of small molecules can comprise a plurality of nicotinamide riboside molecules or nicotinamide riboside analogs.
- the plurality of small molecules can comprise a plurality of caffeine molecules.
- the plurality of small molecules can comprise a plurality of theacrine molecules.
- the plant-derived protein can be from a first source and the one or more phytochemicals can be from a second source that differs from the first source.
- the first source can be from a first plant species and the second source can be from a second plant species.
- the plant-derived protein can be pea protein.
- the plant-derived protein can be water soluble.
- the plant-derived protein can be banana protein, okra protein, or bean protein.
- the bean protein can be soybean protein.
- the phytochemicals can be derived from mango, tea leaf, okra, berry, or grape.
- the phytochemicals can be derived from mango peel powder, dried tea leaf, okra extract powder, berry extract, or grape extract.
- the one or more phytochemicals can comprise a mangiferin, a catechin, or a quercetin.
- the one or more phytochemicals can comprise quercetin and the weight ratio of the one or more phytochemicals to the plant-derived protein can be between 1 : 10000 and 1 :40000.
- the one or more phytochemicals can comprise quercetin and the weight ratio of the one or more phytochemicals to the plant-derived protein can be between 1 :22000 and 1 :23000.
- the one or more phytochemicals can comprise mangiferin, and the weight ratio of the one or more phytochemicals to the plant-derived protein can be between 1 :20 and 1 :60.
- the one or more phytochemicals can comprise mangiferin, and the weight ratio of the one or more phytochemicals to the plant-derived protein can be between 1 :30 and 1 :50.
- the one or more phytochemicals can comprise catechin, wherein the catechin is epigallocatechin gallate.
- the weight ratio of the epigallocatechin gallate to the plant-derived protein can be between 1 :200 and 1 :400.
- the one or more phytochemicals can comprise a polyphenol.
- the polyphenol can comprise one or more of a flavonoid and resveratrol.
- the weight ratio of the one or more phytochemicals to the plant-derived protein can be between 1 :300 and 1 :500.
- the mixture can comprise a dry -weight ratio of the plurality of ketone molecules to plant-derived protein between 1 : 1 and 1 :5.
- the mixture can comprise a weight ratio of plant-derived protein to water between 1 :50 and 1 : 100 or between 1 : 10 and 1 : 100.
- the method can further comprise mixing the mixture with ethanol.
- Mixing the mixture with ethanol to produce particles comprising ketone molecules or NR molecules can be performed by adding the ethanol to the soluble fraction at a 1 : 10 to 1 : 1 ratio by volume of the ethanol to the soluble fraction.
- Mixing the mixture with ethanol to produce particles comprising ketone molecules or NR molecules can be performed by adding the ethanol to the soluble fraction at a 1 : 10 to 1 :5 ratio by volume of the ethanol to the soluble fraction.
- Mixing the mixture with ethanol to produce particles comprising ketone or NR molecules can be performed by adding the ethanol to the soluble fraction at a 1 :4 to 1 :2 ratio by volume of the ethanol to the soluble fraction.
- the method can comprise removing the ethanol. Removing the ethanol can comprise evaporation of the ethanol at from 25°C to 40°C.
- the particles can have an average diameter greater than 80 nm.
- the particles can have an average diameter less than 700 nm.
- the particles can have an average diameter between 100 nm and 500 nm.
- the particles can have an average diameter between 300 nm and 500 nm.
- Removing the ethanol can comprise evaporation of the ethanol at from 25 °C to 40 °C.
- the method can further comprise cross-linking the phytochemicals to the plant protein.
- the phytochemical can be cross-linked to the plant protein via an imine linkage.
- the crosslinking can be performed without an addition of an aldehyde.
- the aldehyde can be glutaraldehyde.
- the cross-linking can occur at one or more functional amino acid groups of the plant protein.
- the functional amino acid group can comprise a primary amino group.
- the functional amino acid groups can comprise lysine.
- the mixture can comprise a soluble fraction and an insoluble fraction.
- the method can comprise, separating the soluble fraction from the insoluble fraction.
- the soluble fraction can be mixed with ethanol. Separating the soluble fraction from the insoluble fraction can comprise filtering the insoluble fraction from the soluble fraction.
- the plurality of small molecules can comprise 1,3 Dihydroxypropan-2-yl (R)-3-hydroxybutanoate. At least 50% of the small molecules can be 1,3 Dihydroxypropan-2-yl (R)-3-hydroxybutanoate. At least 50% of the small molecules can comprise a glyceryl backbone conjugated to a 3-hydroxybutanoate.
- the plurality of small molecules can comprise nicotinamide riboside. In some embodiments, at least 50% of the small molecules are nicotinamide riboside. In some embodiments, the plurality of small molecules can comprise caffeine. In some embodiments, at least 50% of the small molecules are caffeine. In some embodiments, the plurality of small molecules can comprise theacrine. In some embodiments, at least 50% of the small molecules are theacrine.
- Mixing can be performed from 20 °C to 30 °C.
- Mixing can be performed at a pH of 3.5 to 11.0.
- Mixing can be performed at a pH of 3.5 to 7.0, 5.0 to 9.0, or 7.0 to 11.0.
- the plant-derived protein can be water soluble.
- the plant-derived protein can be at least 95% water soluble.
- the plant-derived protein can be at least 98% water soluble.
- the plant- derived protein can be at least 99% water soluble.
- a nano-encapsulated composition formed by the above method.
- a composition comprising a small molecule encapsulated within a plant protein.
- the plant protein can be pea protein.
- the plant protein can be okra protein, banana protein, or bean protein.
- the plant protein can be cross-linked with one or more phytochemicals.
- the one or more phytochemicals can be derived from mango, tea leaf, okra, berry, or grape.
- the one or more phytochemicals can be derived from mango peel powder, dried leaf, okra extract powder, berry extract, or grape extract.
- the one or more phytochemicals can comprise a mangiferin, a catechin, or a quercetin.
- the catechin can be epigallocatechin gallate.
- the one or more phytochemicals can comprise a polyphenol.
- the polyphenol can comprise one or more of a flavonoid and resveratrol.
- the one or more phytochemicals can be cross-linked to the plant protein via an imine linkage. The cross-linking can occur at functional amino acid groups of the plant protein.
- the functional amino acid groups can comprise a primary amine.
- the small molecule can comprise a ketone molecule.
- the ketone molecule can comprise 1,3 Dihydroxypropan-2-yl (R)-3-hydroxybutanoate.
- the small molecule can comprise a nicotinamide riboside molecule or an analog thereof.
- the small molecule can comprise a caffeine molecule.
- the small molecule can comprise a theacrine molecule.
- the particle can have an average diameter greater than 80 nm.
- the particle can have an average diameter less than 700nm.
- the particle can have an average diameter between lOOnm and 500 nm.
- the particle can have a diameter of between 300 nm and 500 nm.
- the composition can have a phenol content greater than lOmg GAE/g.
- the composition can have a phenol content less than or equal to 350 mg GAE/g.
- the composition can have a phenol content between 10 and 500 mg GAE/g.
- the composition can have a phenol content between 100 and 400 mg GAE/g.
- the composition can have a phenol content between 200 and 300 mg GAE/g.
- the composition does not comprise glutaraldehyde.
- FIG. 1 shows a UV-visible spectra of ketone molecules at 2 mg/mL.
- FIG. 2 shows a UV-visible absorption spectra of NR at 0.2 mg/mL.
- FIG. 3 shows 'H NMR of ketone molecules in D2O.
- FIG. 4 shows 'H NMR of NR molecules in D2O.
- FIG. 5 shows 13 C NMR of ketone molecules in D2O.
- FIG. 6 shows 13 C NMR of ketone molecules in D2O.
- FIG. 7 shows 13 C NMR of ketone molecules in D2O.
- FIG. 8 shows 13 C NMR of NR molecules in D2O.
- FIG. 9 shows electrospray ionization-mass spectrometry (ESLMS) spectra of ketone molecules.
- FIG. 10 shows electrospray ionization- mass spectrometry (ESLMS) spectra of NR molecules.
- FIG. 11 shows a graph of GC-MS analysis of ketone molecules.
- FIG. 12 shows graphs of LC-MS analysis of ketone molecules.
- FIG. 13 shows ketone molecule CD spectrum (wavelength versus ellipticity) wherein the positive peak indicates a R/D configuration of the ketone molecules.
- FIG. 14A shows NR molecule CD spectrum (wavelength versus ellipticity) wherein the negative peak indicates a S/L configuration of the NR molecules.
- FIG. 14B shows graphs of LC-MS analysis of caffeine (CA) molecule.
- FIG. 14C shows graphs of LC-MS analysis of theacrine (TH) molecule.
- FIG. 15 shows a schematic of the preparation of KM-protein nanoparticles by a desolvation method.
- FIG. 16 shows a schematic of the preparation of NR-protein nanoparticles by a desolvation method.
- FIG. 17A shows the UV- visible absorption spectra of water-soluble pea protein at 0.2 mg/mL.
- FIG. 17B shows the fluorescence emission spectra of water-soluble pea protein at 0.2 mg/mL at 285 nm excitation.
- FIG. 18 shows MALDI-MS analysis of water-soluble pea protein.
- FIG. 19 shows TEM images of ketone molecules encapsulated by pea protein nanoparticles, produced by ethanol desolvation, crosslinked with mango peel derived phytochemicals.
- FIG. 20 A shows TEM images of NR molecules encapsulated by pea protein nanoparticles, produced by ethanol desolvation, crosslinked with mango peel derived phytochemicals.
- FIG. 20B shows TEM image of CA molecules encapsulated by pea protein nanoparticles, crosslinked with mango peel derived phytochemicals.
- FIG. 20C shows TEM image of TH molecules encapsulated by pea protein nanoparticles, crosslinked with mango peel derived phytochemicals.
- FIG. 21 shows fluorescence emission spectra of KM-PP-MP-NP and PP-MP-NP at 285 nm excitation.
- FIG. 22A shows cell viability of human aortic endothelial cells (HAEC) after 24, 48 and 72 hours post incubation with KM. The control is untreated cells.
- HAEC human aortic endothelial cells
- FIG. 22B shows cell viability of human aortic endothelial cells (HAEC) after 24, 48 and 72 hours post incubation with KM encapsulated pea protein nanoparticles with mango peel crosslinking (KM-PP-MP-NP). KM concentration in KM-PP-MP-NP used for plotting. The control is untreated cells.
- HAEC human aortic endothelial cells
- FIG. 23 shows TEM images of KM encapsulated Pea Protein Nanoparticles by ethanol desolvation method and Tea Extract crosslinking (KM-PP-TE-NP).
- FIG. 24 A shows TEM images of NR encapsulated Pea Protein Nanoparticles by ethanol desolvation method and Tea Extract crosslinking (NR-PP-TE-NP).
- FIG. 24B shows TEM image of CA encapsulated Pea Protein Nanoparticles by Tea Extract crosslinking (CA-PP-TE-NP).
- FIG. 24C shows TEM image of TH encapsulated Pea Protein Nanoparticles by Tea Extract crosslinking (TH-PP-TE-NP).
- FIG. 25 shows fluorescence emission spectra of KM-PP-TE-NP and PP-TE-NP at 285 nm excitation.
- FIG. 26A shows cell viability of human aortic endothelial cells (HAEC) after 24, 48 and 72 hours post incubation with KM. The control is untreated cells.
- HAEC human aortic endothelial cells
- FIG. 26B shows cell viability of human aortic endothelial cells (HAEC) after 24, 48 and 72 hours post incubation with KM encapsulated pea protein nanoparticles with tea extract crosslinking (KM-PP-TE-NP). KM concentration in KM-PP-MP-NP used for plotting. The control is untreated cells.
- HAEC human aortic endothelial cells
- FIG. 27A shows TEM images of KM encapsulated Pea Protein Nanoparticles by Berry extract crosslinking (KM-PP-BE-NP).
- FIG. 27B shows TEM images of KM encapsulated Pea Protein Nanoparticles by Grape extract crosslinking (KM-PP-GE-NP).
- FIG. 27C shows TEM image of CA encapsulated Pea Protein Nanoparticles by Berry Extract crosslinking (CA-PP-BE-NP).
- FIG. 27D shows TEM image of TH encapsulated Pea Protein Nanoparticles by Berry Extract crosslinking (TH-PP-BE-NP).
- FIG. 28 shows total polyphenol content of plant-based crosslinked KM encapsulated pea protein nanoparticles.
- GAE gallic acid equivalent
- FIG. 29 shows Okra mucilage MALDI-MS analysis.
- FIG. 30 shows UV-visible absorption spectra of okra mucilage.
- FIG. 31 shows TEM images of KM encapsulated Okra Extract Nanoparticles (KM-OE- NP).
- FIG. 32 shows TEM images of NR encapsulated Okra Extract Nanoparticles (NR-OE- NP).
- FIG. 33 shows UV-visible absorption spectra of water-soluble Soy Protein Isolate (SPI) (0.2 mg/ml).
- FIG. 34 shows Soy Protein Isolate (SPI) MALDI-MS analysis.
- FIG. 35 shows TEM images of KM encapsulated Soy Protein Isolate Nanoparticles by ethanol desolvation method (KM-SPI-NP).
- FIG. 36 shows pea protein KM nanoparticle synthesis utilizing biocompatible plantbased crosslinking agents.
- FIG. 37 shows TEM images of KM-encapsulated pea protein nanoparticles by ethanol desolvation method and plant-based crosslinking (a-mangiferin from mango peel extract, b- EGCG from tea extract, c-quercetin from black berry extract and d-resveratrol from grape extract).
- FIG. 38 shows the creation of plant protein-phytochemical platform through interactions of phytochemicals with protein amino side chains.
- FIG. 39 shows ketone molecule bonding with plant-derived proteins and phytochemicals.
- FIG. 40 shows 'H NMR of KM in D 2 O.
- FIG. 41 shows T H NMR of water-soluble Pea Protein (PP) in D 2 O.
- FIG. 42 shows 'H NMR of mangiferin in CD 3 OD.
- FIG. 43 shows (expanded) of mangiferin and water-soluble Pea Protein (PP) reaction mixture in CD3OD/D 2 O (arrows indicate change in proton).
- FIG. 44 shows (expanded) of mangiferin, water soluble Pea Protein (PP) and KM reaction mixture in CD3OD/D 2 O.
- FIG. 45 shows of epigallocatechin gallate (EGCG) in D 2 O.
- FIG. 46 shows (expanded) of epigallocatechin gallate (EGCG) and water- soluble Pea Protein (PP) reaction mixture in D 2 O (arrows indicate change in proton).
- EGCG epigallocatechin gallate
- PP water- soluble Pea Protein
- FIG. 47 shows 1H NMR (expanded) of epigallocatechin gallate (EGCG), water soluble
- FIG. 48 shows T H NMR of quercetin in CD3OD.
- FIG. 49 shows H NMR (expanded) of quercetin and water-soluble Pea Protein (PP) reaction mixture in CD3OD/D2O (arrows indicate change in proton).
- FIG. 50 shows (expanded) of quercetin, water-soluble Pea Protein (PP) and KM reaction mixture in CD3OD/D 2 O.
- FIG. 51 shows 'H NMR of resveratrol in CD3OD.
- FIG. 52 shows (expanded) of resveratrol and water-soluble Pea Protein (PP) reaction mixture in CD3OD/D 2 O (arrows indicate change in proton).
- FIG. 53 shows (expanded) of resveratrol, water-soluble Pea Protein (PP) and KM reaction mixture in CD3OD/D 2 O.
- FIG. 54 shows the amino acid composition of pea protein (gram per 100 g protein).
- FIG. 55 shows the amino acid composition of okra extract (gram per 100 g protein).
- FIG. 56 shows the amino acid composition of soy protein isolate (gram per 100 g protein).
- FIG. 57 shows the comparison of the amino acid composition of pea protein, okra extract, and soy protein isolate (gram per 100 g protein).
- FIG. 58 shows the polyphenolic composition distribution (milligram per gram dry matter) of mango peel powder obtained from mango fruit.
- FIG. 59 shows the polyphenolic composition distribution (milligram per gram dry matter) of black tea leaves.
- FIG. 60 shows the anthocyanins and non-anthocyanin phenolic compound composition (microgram per 100-gram dry matter) of Blackberry Extract (BE).
- FIG. 61 shows the polyphenolic composition distribution (milligram per gram dry matter) of grape extract.
- Plant based proteins are biocompatible, economically viable, and generally safe for use as nutraceuticals or as smart foods/pharmaceuticals.
- Disclosed here are systems and methods to encapsulate ketone molecules (KM), nicotinamide riboside (NR) molecules, and their analogs to enhance stability, enhance biocompatibility, and transform these types of food supplement(s)/nutraceutical(s) to be biocompatible, target and cell specific in vivo.
- Also disclosed herein are methods and systems for delivery of NR molecules and analogs thereof.
- Disclosed herein are also analogous systems suitable for encapsulation of other small molecules.
- small molecule refers to molecules of less than or equal to 900 daltons.
- ketone molecule refers to a molecule with the structure of Compound I below, wherein R 1 , R 2 and R 3 can be H or -C4H6O2 and at least one of R 1 , R 2 and R 3 is -C4H6O2
- Compound I can comprise any of Compounds II-V below.
- -C4H6O2 is
- nicotinamide riboside refers to a molecule with the structure of Compound VI below.
- analogs of nicotiamide riboside molecule can comprise any of the Compounds VII- IX below.
- caffeine refers to a molecule with the structure of Compound X below.
- the term “theacrine” as described herein refers to a molecule with the structure of Compound XI below.
- the term “plurality of ketone molecules” as described herein can refer to any plurality of ketone molecules.
- the plurality of ketone molecules are at least 70% Compound II.
- the plurality of ketone molecules can be greater than or equal to 99%, 98%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60% 55% of 50% Compound II.
- the plurality of ketone molecules can be less than or equal to 50%, 40%, 30%, 20%, 10%, 5%, or 1% Compound III, Compound IV, or Compound V.
- the molar ratio of Compound II to a mixture of Compounds III-V in solution can be between 80:20 and 99: 1.
- the molar ratio of Compound II to a mixture of Compounds III-V in solution can be greater than or equal to about 80:20, 85: 15, 90: 10, 95:5, or 99: 1.
- the molar ratio of Compound II to a mixture of Compounds III-V in solution can be less than or equal to 99: 1, 95:5, 90: 10, 85: 15, or 80:20.
- the term “plurality of nicotinamide riboside molecules” as described herein can refer to any plurality of nicotinamide riboside molecules.
- the plurality of NR molecules can be nicotinamide riboside hydrogen maleate.
- the plurality of NR molecules can be nicotinamide riboside chloride.
- the plurality of NR molecules are at least 70% Compound VI.
- the plurality of NR molecules can be greater than or equal to 99%, 98%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60% 55% of 50% Compound VI.
- the plurality of NR molecules can be less than or equal to 50%, 40%, 30%, 20%, 10%, 5%, or 1% Compound VII, Compound VIII, or Compound IX.
- encapsulating refers to incorporating a small molecule, such as a ketone, NR, caffeine, or theacrine molecule, into a cross-linked particle, even if the small molecule is not fully surrounded by plant-derived protein or other non-ketone molecules.
- a small molecule such as a ketone, NR, caffeine, or theacrine molecule
- An embodiment of this invention encapsulates ketone, NR, caffeine, or theacrine molecules within plant-based proteins from peas, okra, or banana.
- Ketone, NR, caffeine, or theacrine molecules can be encapsulated within plant-based proteins from peas, okra, or banana using plant-based cross-linking agents including various polyphenols, flavonoids, xanthonoids and functionalized glucose moieties.
- plant-based cross-linking agents including various polyphenols, flavonoids, xanthonoids and functionalized glucose moieties.
- Methods and systems disclosed herein can utilize the ingredients of plant-based proteins and phytochemicals from peas, okra, banana, mango, tea leaves, berries, and grapes to produce particles comprising plant-based proteins loaded with ketone, NR, caffeine or theacrine molecules.
- the methods and systems disclosed herein can be used to produce particles that provide rapid and sustainable energy along with a rich group of key nutrients, including potassium, dietary fiber, polyunsaturated fats, essential amino acids, vitamin B6, vitamin B12, magnesium, potassium, fiber, and protein.
- Fibers from the peas, banana and okra can contribute to gastrointestinal function and health.
- the amylose contents in such plant-based protein extracts can help in lowering glycemic index.
- the hydrolysis products of pea protein encapsulated ketone, NR, caffeine, or theacrine molecules can generate peptides with bioactivity, for example peptides capable of angiotensin I-converting enzyme inhibitor activity and antioxidant activity.
- the plant-derived protein particles described herein can provide polyphenolics with antioxidant, anticarcinogenic, or hypocholesterolemia activities.
- the plant-derived protein encapsulated ketone particles can provide prebiotic effects, such as from the galactose oligosaccharides, in the large intestine.
- ketone molecule within a plant-derived protein crosslinked with a phytochemical.
- the ketone molecule is bound to the plant-derived protein and phytochemical via hydrogen bonds as can be seen in FIG. 39.
- Ketone Molecule (KM) The structure of the Ketone Molecule (KM) and the respective Fischer esterification scheme involving the dehydration of the parent carboxylic acid [(R)-3 -hydroxybutyric acid] and the corresponding alcohol (glycerol) is shown below:
- the parent alcohol glycerol can contain both primary and secondary alcohol groups.
- Nicotinamide riboside molecules [0121] Nicotinamide riboside molecules
- Nicotinamide riboside is a precursor of nicotinamide adenine dinucleotide (NAD+).
- NAD+ is an essential coenzyme involved in various metabolic pathways, and an elevated NAD+ content in the body may provide health benefits.
- NR and NR analogs are shown below:
- CA Caffeine
- CNS central nervous system
- Coffee bean is a major source of CA, and it tastes bitter.
- CA is classified by the US FDA as GRAS. Up to 400 mg of caffeine per day is safe. Toxic doses is over 10 grams per day for an adult.
- Theacrine (TH) is a purine alkaloid, structurally similar to caffeine. It improves mood, energy and focus. Cupuagu (tropical rainforest tree) and Chinese tea (kuchas) are major sources of TH. It affects adenosine signaling similar to caffeine. It is clinically safe and has nonhabituating effects in humans. Daily use of up to 300 mg/day TH is safe.
- Crosslinking agents may be beneficial for the synthesis of Ketone molecule (KM), NR, caffeine or theacrine encapsulated protein nanoparticles. Crosslinking agents crosslink the protein amino groups to form denser particles.
- a common chemical crosslinker used for protein nanoparticle synthesis is glutaraldehyde. It is an effective crosslinking agent imparting nanoparticle stability and sustained drug release. Although effective, it may exert measurable systemic toxicity to humans especially when used for extended periods. As there no alternative non-toxic cross-linking agents, food, beverage, and pharmaceutical industries have continued to use glutaraldehyde in lower concentrations although the fear of long-term systemic toxicities with irreversible adverse toxic effects on human health persist.
- Plantbased materials including mangiferin (MGF), catechin, epigallocatechin gallate (EGCG), quercetin (QUE), and resveratrol (RESV) can be utilized for effective crosslinking and encapsulation of ketone molecules (KM) (FIG. 23), NR molecules (FIG. 24A), CA molecule (FIGS. 20B and 24B) and TH molecule (FIGS. 20C and 24C).
- KM ketone molecules
- NR molecules FIG. 24A
- CA molecule FIGS. 20B and 24B
- TH molecule TH molecule
- Crosslinking agents can bind to the protein amino groups to form particles.
- the common chemical cross-linker used for protein nanoparticle synthesis is glutaraldehyde.
- Disclosed herein are methods and systems that cross-link plant derived protein without glutaraldehyde. Disclosed herein at methods and products that do not include glutaraldehyde.
- biocompatible plant-based cross-linking agents including naturally available cross-linkers from tea (Epigallocatechin gallate; EGCG), mango (Mangiferin; MGF and various family of polyphenols and xanthonoids), berries (Quercetin; QUE), and grapes (Resveratrol; RESV).
- Mangiferin a xanthonoid
- Mangiferin can be isolated from the leaves and bark of Mangifera indica (mango). It can also be extracted from mango peel (MP) and the kernel.
- Catechin a natural phenol, belongs to the flavonoid family. It is found in tea and fruits and is an antioxidant.
- EGCG epigallocatechin gallate
- EGCG is a catechin formed by the esterification of gallic acid and epigallocatechin.
- Polyphenols such as EGCG and catechin are found abundantly in tea leaves.
- Quercetin a polyphenol belonging to the flavonoid group is widely found in fruits and vegetables. Quercetin is the most abundant polyphenol in black berry extract.
- the predominant phytochemical of grape extract is trans-resveratrol, as can be seen in FIG. 61.
- Resveratrol a stilbene-based plant phenol is found in grape extract.
- Resveratrol (RESV) is a stilbenoid, a form of natural phenol and a phytoalexin predominantly found in grape skin.
- the respective phytoextract is a phytochemical cocktail containing various other active ingredients which can also play a role in the crosslinking and encapsulation process whilst adding nutraceutical value to the formulation.
- Plant-derived protein [0149] Plant-derived protein:
- Proteins described herein can be derived from plants such as beans, okra, and pea.
- Bean protein can be soybean protein.
- Plant-derived protein can be water-soluble.
- Water-soluble protein can be hydrolyzed plant protein.
- FIG. 57 shows a comparison of the amino acid composition of pea protein, okra extract, and soy protein isolate.
- Water soluble pea protein can be derived from pea protein.
- Pea protein can be refined using enzyme digestion, filtration, or spray-drying.
- the protein content of pea protein can be >85%.
- Pea proteins can exist as globulins (65-80%) and can be composed of legumin, vicilin, and minor contributions from convicilin proteins.
- Pea protein can contain less than 7% moisture, less than 7% ash, and less than 7% crude fiber.
- Pea protein can have a pH between 5.0 and 6.0 when dissolved in water.
- the amino acid composition of pea protein can be found in FIG. 54.
- Okra Extract (Abelmoschus esculentus L.) can contain water (90%), protein (2%), carbohydrates (7%) and trace amounts of fat.
- Okra extract is a source of dietary fiber, vitamin C and vitamin K.
- Okra mucilage or gel from the pods is a natural polysaccharide and consists of D- galactose, L-rhamnose and L-galacturonic acid.
- Okra extract can be extracted in water and forms a gelatinous viscous solution. The amino acid composition of okra extract can be found in FIG. 55.
- Soy Protein Isolate is derived from soybean. Soy protein isolate can be composed of P-conglycinin, glycinin, and lipophilic proteins. Soy protein can have a protein content of 92% (in dry basis). Additionally, it can contain moisture 6%, Ash 4.1%, Fat (PE extract) 0.8%, crude fiber (crude) 0.25%, calcium 0.15%, phosphorus 0.8%, sodium 1.3%, potassium 0.05%, and can display a pH (water slurry) of 7.1. The amino acid composition of soy protein isolate can be found in FIG. 56.
- kits may include one or more containers housing one or more of the components provided in this disclosure and instructions for use. Specifically, such kits may include one or more compositions described herein, along with instructions describing the intended application and the proper use and/or disposition of these compositions. Kits may contain the components in appropriate concentrations or quantities for running various experiments. [0155] Methods of manufacturing nanoparticles
- nanoparticles comprising plant- derived protein crosslinked with one or more phytochemicals as described herein.
- the nanoparticles can encapsulate one or more small molecules, such as ketone molecules, nicotinamide riboside molecules, caffeine molecules and/or theacrine molecules.
- plant-derived protein, phytochemical containing powder, and ketone molecules are combined in water.
- plant-derived protein, phytochemical containing powder, and NR molecules are combined in water.
- plant-derived protein, phytochemical containing powder, and caffeine molecules are combined in water.
- plant-derived protein, phytochemical containing powder, and theacrine molecules are combined in water.
- ethanol is added to a mixture of plant-derived protein, phytochemical containing powder, and ketone molecules. In some embodiments, ethanol is added to a mixture of plant-derived protein, phytochemical containing powder, and NR molecules. In some embodiments, the ethanol is added to the mixture at a 1 : 10 to 1 : 1 ratio by volume of ethanol to mixture. In some embodiments, the volume ratio of ethanol to mixture is greater than or equal to: 1 : 10, 1 :9, 1 :8, 1 :7, 1 :6, 1 :5, 1 :4, 1 :3, 1 :2, or 1 : 1.
- the volume ratio of ethanol to mixture is less than or equal to 1 : 1, 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9, or 1 : 10. In some embodiments, the volume ratio of ethanol to mixture is between 1 :4 and 1 :7, 1 :5 and 1 :9, or 1 :6 and 1 : 10. In some embodiments, the volume ratio of ethanol to mixture is less than or equal to 1 :7. In some embodiments, the ethanol is removed from the mixture of plant-derived protein, phytochemical containing powder, and ketone molecules. In some embodiments, the ethanol is removed from the mixture of plant-derived protein, phytochemical containing powder, and NR molecules. In some embodiments, the ethanol is removed from the mixture by incubating the mixture at a temperature greater than or equal to 37°C. In some embodiments the ethanol is removed by rotovapor evaporation.
- the phytochemical containing powder comprises tea leaves, blackberry, grape, mango, or okra. In some embodiments, the phytochemical containing powder comprises loose-leaf tea, black berry powder, grapes, mango peel powder, or okra extract powder. In some embodiments, the concentration of phytochemical in the phytochemical containing powder is greater than or equal to 90 pg/g dry matter, 1 mg/g dry matter, 170 mg/g dry matter, or 950 mg/g dry matter.
- the phytochemical containing powder is mango peel powder.
- the phytochemical of mango peel powder is mangiferin.
- the concentration of phytochemical in mango peel powder is less than or equal to 200 mg/g dry matter, 190 mg/g dry matter, 180 mg/g dry matter, 170 mg/g dry matter, 160 mg/g dry matter, 150 mg/g dry matter, 140 mg/g dry matter, 130 mg/g dry matter, 120 mg/g dry matter, 110 mg/g dry matter, or 100 mg/g dry matter.
- the concentration of phytochemical in mango peel powder is greater than or equal to 100 mg/g dry matter, 110 mg/g dry matter, 120 mg/g dry matter, 130 mg/g dry matter, 140 mg/g dry matter, 150 mg/g dry matter, 160 mg/g dry matter, 170 mg/g dry matter, 180 mg/g dry matter, 190 mg/g dry matter, or 200 mg/g dry matter.
- the concentration of phytochemical in mango peel powder is between 100 mg/g to 120 mg/g dry matter, between 110 mg/g to 130 mg/g dry matter, between 120 mg/g to 140 mg/g dry matter, between 150 mg/g to 170 mg/g dry matter, between 160 mg/g to 180 mg/g dry matter, between 170 mg/g to 190 mg/g dry matter, or between 180 mg/g to 200 mg/g dry matter.
- the weight ratio of mangiferin to plant-derived protein is greater than or equal to 1 :60, 1 :55, 1 :50, 1 :45, 1 :40, 1 :35, or 1 :30. In some embodiments, the weight ratio of mangiferin to plant-derived protein is less than or equal to 1 :30, 1 :35, 1 :40, 1 :45, 1 :50, 1 :55, or 1 :60.
- the weight ratio of mangiferin to plant-derived protein is between 1 :30 and 1 :40, between 1 :35 and 1 :45, between 1 :40 and 1 :50, between 1 :45 and 1 :55, or between 1 :50 and 1 :60. In some embodiments, the weight ratio of mangiferin to plant-derived protein is 1 :40.
- the phytochemical containing powder comprises tea leaves.
- the phytochemical of tea leaves is Epigallocatechin 3- O-gallate (EGCG).
- the concentration of phytochemical in tea leaves is less than or equal to 1050 mg/g dry matter, 1000 mg/g dry matter, 950 mg/g dry matter, 900 mg/g dry matter, 850 mg/g dry matter, 800 mg/g dry matter, 750 mg/g dry matter, 700 mg/g dry matter, 650 mg/g dry matter, 600 mg/g dry matter, 550 mg/g dry matter, or 500 mg/g dry matter.
- the concentration of phytochemical in tea leaves is greater than or equal to 500 mg/g dry matter, 550 mg/g dry matter, 600 mg/g dry matter, 650 mg/g dry matter, 700 mg/g dry matter, 750 mg/g dry matter, 800 mg/g dry matter, 850 mg/g dry matter, 900 mg/g dry matter, 950 mg/g dry matter, 1000 mg/g dry matter, or 1050 mg/g dry matter.
- the concentration of phytochemical in tea leaves is between 500 mg/g to 600 mg/g dry matter, between 550 mg/g to 650 mg/g dry matter, between 600 mg/g to 700 mg/g dry matter, between 650 mg/g to 750 mg/g dry matter, between 700 mg/g to 800 mg/g dry matter, between 750 mg/g to 850 mg/g dry matter, between 800 mg/g to 900 mg/g dry matter, between 850 mg/g to 950 mg/g dry matter, between 900 mg/g to 1000 mg/g dry matter or between 950 mg/g to 1050 mg/g dry matter.
- the weight ratio of EGCG to plant-derived protein is greater than or equal to 1 :500, 1 :450, 1 :400, 1 :350, 1 :300, 1 :250, 1 :200, 1 : 150, or 1 : 100. In some embodiments, the weight ratio of EGCG to plant-derived protein is less than or equal to 1 : 100, 1 : 150, 1 :200, 1 :250, 1 :300, 1 :350, 1 :400, 1 :450, or 1 :500.
- the weight ratio of EGCG to plant-derived protein is between 1 : 100 and 1 :200, between 1 : 150 and 1 :250, between 1 :200 and 1 :300, between 1 :250 and 1 :350, between 1 :300 and 1 :400, between 1 :350 and 1 :450, or between 1 :400 and 1 :500. In some embodiments, the weight ratio of EGCG to plant-derived protein is 1 :265.
- the phytochemical containing powder comprises grape extract.
- the phytochemical of grape extract is trans-resveratrol
- the concentration of phytochemical in grape extract is less than or equal to 40 mg/g dry matter, 35 mg/g dry matter, 30 mg/g dry matter, 25 mg/g dry matter, 20 mg/g dry matter, 19 mg/g dry matter, 18 mg/g dry matter, 17 mg/g dry matter, 16 mg/g dry matter, 15 mg/g dry matter, 14 mg/g dry matter, 13 mg/g dry matter, 12 mg/g dry matter, 11 mg/g dry matter, 10 mg/g dry matter, 9 mg/g dry matter, 8 mg/g dry matter, 7 mg/g dry matter, 6 mg/g dry matter, 5 mg/g dry matter, 4 mg/g dry matter, 3 mg/g dry matter, 2 mg/g dry matter, or 1 mg/g dry matter.
- the concentration of phytochemical in grape extract is greater than or equal to 1 mg/g dry matter, 2 mg/g dry matter, 3 mg/g dry matter, 4 mg/g dry matter, 5 mg/g dry matter, 6 mg/g dry matter, 7 mg/g dry matter, 8 mg/g dry matter, 9 mg/g dry matter, 10 mg/g dry matter, 11 mg/g dry matter, 12 mg/g dry matter, 13 mg/g dry matter, 14 mg/g dry matter, 15 mg/g dry matter, 16 mg/g dry matter, 17 mg/g dry matter, 18 mg/g dry matter, 19 mg/g dry matter, 20 mg/g dry matter, 25 mg/g dry matter, 30 mg/g dry matter, 35 mg/g dry matter, or 40 mg/g dry matter.
- the concentration of phytochemical in grape extract is between 1 mg/g to 3 mg/g dry matter, between 2 mg/g to 4 mg/g dry matter, between 5 mg/g to 7 mg/g dry matter, between 6 mg/g to 8 mg/g dry matter, between 7 mg/g to 9 mg/g dry matter, between 8 mg/g to 10 mg/g dry matter, between 9 mg/g to 11 mg/g dry matter, between 10 mg/g to 12 mg/g dry matter, between 11 mg/g to 13 mg/g dry matter, between 12 mg/g to 14 mg/g dry matter, between 13 mg/g to 15 mg/g dry matter, between 14 mg/g to 16 mg/g dry matter, between 15 mg/g to 17 mg/g dry matter, between 16 mg/g to 18 mg/g dry matter, between 17 mg/g to 19 mg/g dry matter, between 18 mg/g to 20 mg/g dry matter, between 19 mg/g to 25 mg/g dry matter, between 20 mg/g to 30 mg/g dry matter, between 25 mg/g to 35,
- the weight ratio of resveratrol to plant-derived protein is greater than or equal to 1 :500, 1 :450, 1 :400, 1 :350, or 1 :300. In some embodiments, the weight ratio of resveratrol to plant-derived protein is less than or equal to 1 :300, 1 :350, 1 :400, 1 :450, or 1 :500. In some embodiments, the weight ratio of resveratrol to plant-derived protein is between 1 :300 and 1 :400, between 1 :350 and 1 :450, or between 1 :400 and 1 :500. In some embodiments, the weight ratio of resveratrol to plant-derived protein is 1 :400.
- the phytochemical containing powder comprises blackberry.
- the phytochemical of blackberry is quercetin.
- the concentration of phytochemical in blackberry is less than or equal to lOOOOpg/lOOg dry matter, 95000 pg/lOOg dry matter, 90000 pg/lOOg dry matter, 85000 pg/lOOg dry matter, 80000 pg/lOOg dry matter, 75000 pg/lOOg dry matter, 70000 pg/lOOg dry matter, 65000 pg/lOOg dry matter, 60000 pg/ 100g dry matter, 55000 pg/ 100g dry matter, or 50000 pg/ 100g dry matter.
- the concentration of phytochemical in blackberry is greater than or equal to 50000 pg/lOOg dry matter, 55000 pg/lOOg dry matter, 60000 pg/lOOg dry matter, 65000 pg/lOOg dry matter, 70000 pg/lOOg dry matter, 75000 pg/lOOg dry matter, 80000 pg/lOOg dry matter, 85000 pg/lOOg dry matter, 90000 pg/lOOg dry matter, 95000 pg/lOOg dry matter, or 100000 pg/lOOg dry matter.
- the concentration of phytochemical in blackberry is between 50000 pg/lOOg to 60000 pg/lOOg dry matter, between 55000 pg/lOOg to 65000 pg/lOOg dry matter, between 60000 pg/lOOg to 70000 pg/lOOg dry matter, between 65000 pg/lOOg to 75000 pg/lOOg dry matter, between 70000 pg/lOOg to 80000 pg/lOOg dry matter, between 75000 pg/lOOg to 85000 pg/lOOg dry matter, between 80000 pg/lOOg to 90000 pg/lOOg dry matter, between 85000 pg/lOOg to 95000 pg/lOOg dry matter, or between 90000 pg/lOOg to 100000 pg/lOOg dry matter.
- the weight ratio of quercetin to plant-derived protein is greater than or equal to 1 :40000, 1 :35000, 1 :30000, 1 :25000, 1 :24000, 1 :23500, 1 :23,000, 1 :22,750, 1 :22,500, 1 :22,250, or 1 :22,000. In some embodiments, the weight ratio of quercetin to plant- derived protein is less than or equal to 1 :22,000, 1 :22,250, 1 :22,500, 1 :22,750, 1 :23,000, 1 :23500, 1 :24000, 1 :25000, 1 :30000, or 1 :40000.
- the weight ratio of quercetin to plant-derived protein is between 1 :22,000 and 1 :22,500, between 1 :22,250 and 1 :22,750, between 1 :22,500 and 1 :23,000, between 1 :22,750 and 1 :23,500, between 1 :23,000 and 1 :24,000, between 1 :23,500 and 1 :25,000, between 1 :24,000 and 1 :30,000, or between 1 :25,000 and 1 :40,000.
- the weight ratio of quercetin to plant-derived protein is 1 :22,222.
- the water has undergone one or more processes such as distillation or filtration.
- the water is distilled water.
- the dry weight ratio of ketone molecules to plant-derived protein is less than or equal to 1 : 1, 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9, or 1 : 10. In some embodiments, the dry weight ratio of ketone molecules to plant-derived protein is greater than or equal to 1 : 10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, or 1:1. In some embodiments, the dry weight ratio of ketone molecule to plant-derived protein is between 1:10 and 1:1, between 1:5 and 1 :2, or between 1 :3 and 1 :2. In some embodiments, the dry weight ratio of ketone molecule to plant-derived protein is less than or equal to 1 :2. In some embodiments, the dry weight ratio of ketone molecule to plant-derived protein is 1:2.5.
- the dry weight ratio of NR molecules to plant-derived protein is less than or equal to 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10. In some embodiments, the dry weight ratio of NR molecules to plant-derived protein is greater than or equal to 1:10, 1 :9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, or 1:1. In some embodiments, the dry weight ratio of NR molecule to plant-derived protein is between 1:10 and 1:1, between 1:5 and 1 :2, or between 1 :3 and 1 :2. In some embodiments, the dry weight ratio of NR molecule to plant-derived protein is less than or equal to 1 :2. In some embodiments, the dry weight ratio of NR molecule to plant-derived protein is 1:3.2.
- the dry weight ratio of caffeine molecules to plant-derived protein is less than or equal to 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10. In some embodiments, the dry weight ratio of caffeine molecules to plant-derived protein is greater than or equal to 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, or 1:1. In some embodiments, the dry weight ratio of caffeine molecule to plant-derived protein is between 1:10 and 1:1, between 1:5 and 1 :2, or between 1 :3 and 1 :2. In some embodiments, the dry weight ratio of caffeine molecule to plant- derived protein is less than or equal to 1 :2. In some embodiments, the dry weight ratio of caffeine molecule to plant-derived protein is 1:2.
- the dry weight ratio of TH molecules to plant-derived protein is less than or equal to 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10. In some embodiments, the dry weight ratio of TH molecules to plant-derived protein is greater than or equal to 1:10, 1 :9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, or 1:1. In some embodiments, the dry weight ratio of TH molecule to plant-derived protein is between 1:10 and 1:1, between 1:5 and 1 :2, or between 1 :3 and 1 :2. In some embodiments, the dry weight ratio of TH molecule to plant-derived protein is less than or equal to 1 :2. In some embodiments, the dry weight ratio of TH molecule to plant-derived protein is 1:2.
- the weight ratio of plant-derived protein to water is greater than or equal to: 1:100, 1:90, 1:80, 1:70, 1:60, 1:50, 1:40, 1:30, 1:20, or 1:10. In some embodiments, the weight ratio of plant-derived protein to water is less than or equal to 1:10, 1 :20, 1 :30, 1 :40, 1:50, 1:60, 1:70, 1:80, 1:90, or 1:100. In some embodiments, the weight ratio of plant-derived protein to water is between 1 :40 and 1 :70, 1:50 and 1 :90, or 1 :60 and 1 : 100.
- the weight ratio of plant-derived protein to water is less than or equal to 1 :70. In some embodiments, the weight ratio of plant-derived protein to water is 1 :66.7. In some embodiments, the weight ratio of plant-derived protein to water is 1 :20.
- nanoparticles comprising plant-derived protein crosslinked with one or more phytochemicals.
- a nanoparticle can comprise one or more ketone molecules.
- the average diameter of a nanoparticle is less than or equal to 700nm, 600nm, 500nm, 400nm, 300nm, 200nm, lOOnm, 90nm, 80nm, 70nm, 60nm, or 50nm. In some embodiments, the average diameter of a nanoparticle is greater than or equal to 50nm, 60nm, 70nm, 80nm, 90nm, lOOnm, 200nm, 300nm, 400nm, 500nm, 600nm, or 700nm.
- the average diameter of a nanoparticle is between 50nm and 70nm, between 60nm and 80nm, between 70nm and 90nm, between 80nm and lOOnm, between 90nm and 200nm, between lOOnm and 300nm, between lOOnm and 400nm, between 100 nm and 500nm, between 200nm and 400 nm, between 200nm and 50nm, between 300nm and 500nm, between 400nm and 600nm, or between 500nm and 700nm.
- the nanoparticles comprise phenols.
- the phenol content of a nanoparticle is quantified using total gallic acid equivalents (GAE).
- GEE total gallic acid equivalents
- the phenol content of nanoparticles described herein is greater than 5mg GAE/g, 10 mg GAE/g, 20mg GAE/g, 30mg GAE/g, 40mg GAE/g, 50mg GAE/g, 60mg GAE/g, 70mg GAE/g, 80mg GAE/g, 90mg GAE/g, lOOmg GAE/g, 150mg GAE/g, 200 mg GAE/g, 250mg GAE/g, 300 mg GAE/g, or 350 mg GAE/g.
- the phenol content of nanoparticles described herein is less than 400mg GAE/g, 350mg GAE/g, 300mg GAE/g, 250mg GAE/g, 200mg GAE/g, 150mg GAE/g, lOOmg GAE/g, 90mg GAE/g, 80mg GAE/g, 70mg GAE/g, 60mg GAE/g, 50mg GAE/g, 40mg GAE/g, 30mg GAE/g, 20mg GAE/g, lOmg GAE/g, or 5mg GAE/g.
- the phenol content of nanoparticles described herein is between 5mg GAE/g and 20mg GAE/g, between lOmg GAE/g and 30mg GAE/g, between 20mg GAE/g and 40mg GAE/g, between 30mg GAE/g and 50mg GAE/g, between 40mg GAE/g and 60mg GAE/g, between 50mg GAE/g and 70mg GAE/g, between 60mg GAE/g and 80mg GAE/g, between 70mg GAE/g and 90mg GAE/g, between 80mg GAE/g and lOOmg GAE/g, between 90mg GAE/g and 150mg GAE/g, between lOOmg GAE/g and 200mg GAE/g, between 150mg GAE/g and 250mg GAE/g, between 200mg GAE/g and 300mg GAE/g, between 250mg GAE/g and 350
- Ketone molecules as described herein were produced through a Fisher esterification reaction of (R)-3 -hydroxybutyric acid and glycerol, as described herein, resulting in a mixture of Compounds II- V, as described herein.
- Compound II was purified by fractional distillation according to methods known in the art. (See, e.g., www.sciencedirect.com/topics/chemistry/fractional-distillation)
- the resulting ketone molecules comprised a molar ratio of Compound II to Compounds II-V of greater than 80:20.
- Nicotinamide riboside molecules and Compound IV were obtained from Thorne Healthcare.
- Caffeine molecule was obtained from Sigma-Aldrich.
- Theacrine molecule was obtained from BulkStimulants.com.
- Solubility KM was water soluble and was miscible with ethanol. KM was not soluble in methylene chloride.
- pH KM displayed a pH of 4.5 in water indicating an acidic aqueous solution.
- UV-visible absorption spectroscopy The electronic transition in KM pertains to the ultraviolet region (UV) based on the UV-visible absorption measurement. KM showed a broad absorption until -245 nm in the UV region (FIG. 1). There was no chromophoric characteristic absorption peaks in the visible region. Therefore, with regards to tracking KM or KM encapsulated protein nanoparticles, UV-visible spectroscopy was not utilized.
- Nuclear magnetic resonance spectroscopy 1H nuclear magnetic resonance (NMR) spectra was recorded at 300 MHz on a Bruker 300 MHz spectrometer.13C NMR spectra was recorded at 151 MHz on a Bruker 600 MHz spectrometer. NMR spectra was recorded in deuterated water (D2O). The 1H chemical shifts were reported relative to internal D2O (FIG. 3). The 13C NMR chemical shifts were reported relative to an external tetramethylsilane (TMS) standard (FIG. 5-7). KM is a carboxylate ester comprising of the parent carboxylic acid (3- hydroxybutyric acid) and the corresponding alcohol (glycerol).
- Mass Spectrometry A range of sophisticated mass spectrometric techniques had been utilized to develop a reliable quality control parameters for the Ketone Molecule (KM) and its protein encapsulated products. Analysis of KM using electrospray ionization-mass spectrometry (ESI-MS) technique had been carried out. Apart from obtaining the elemental/isotopic signature of KM using MS, the [M+H]+ peak had been used for molecular weight estimation. Based on the chemical structure, the calculated molecular weight of KM was 178.18 g/mole. The [M+Na]+ peak of 201.07 was detected as the major peak indicating the presence of monoglyceride (KM) (FIG. 9).
- ESI-MS electrospray ionization-mass spectrometry
- GC-MS Gas chromatography-mass spectrometry
- LC-MS Liquid chromatography-mass spectrometry
- Circular Dichroism Chiral molecules are mirror images or enantiomers. The physical properties of enantiomers are identical in every way except with regards to how the molecules interact with polarized light and how they interact with other chiral molecules. Enantiomerism is a special form of isomerism. Circular dichroism (CD), measured as a function of wavelength, is the difference in absorbance of left-handed circularly polarized light (L-CPL) and right-handed circularly polarized light (R-CPL). When chiral chromophores are present, one state of circularly polarized light is absorbed to a greater or lesser extent than the other.
- L-CPL left-handed circularly polarized light
- R-CPL right-handed circularly polarized light
- a circular dichroism signal can, therefore, be positive or negative, depending on whether L-CPL is absorbed to a greater extent than R-CPL (CD signal positive relating to R/D configuration) or to a lesser extent (CD signal negative relating to S/L configuration).
- the KM was used for the CD measurement. The concentration of KM was 7 mg/ml in water.
- the starting material (R)-3 -hydroxybutyric acid, also known as D-P- hydroxybutyric acid was chiral and introduced chirality in KM.
- Circular Dichroism (CD) spectrum of KM was positive indicating R/D configuration in KM (FIG. 13).
- KM assessment Analysis of KM showed 80-70 % of the monoglyceride based on NMR and GC-MS respectively. There were no diglycerides and triglycerides based on GC-MS analysis. 10-20 % glycerol and 10 % 3 -hydroxybutyric acid starting materials were also seen in NMR and GC-MS respectively. No other impurities were seen.
- Solubility NR was water soluble and is miscible with ethanol.
- the chloride salt of nicotinamide riboside has good solubility in water.
- pH NR displayed a pH of 4.0 in water indicating an acidic aqueous solution.
- UV-visible absorption spectroscopy The electronic transition in NR pertains to the ultraviolet region (UV) based on the UV-visible absorption measurement. NR showed a broad absorption until -300 nm in the UV region with peaks at 220 nm, 230 nm, and 265 nm (FIG. 2). There was no chromophoric characteristic absorption peaks in the visible region. Therefore, with regards to tracking NR encapsulated protein nanoparticles, UV-visible spectroscopy was not utilized.
- Nuclear magnetic resonance spectroscopy 'H nuclear magnetic resonance (NMR) spectra was recorded at 500 MHz on a Bruker 500 MHz spectrometer. 13 C NMR spectra was recorded at 126 MHz on a Bruker 500 MHz spectrometer. NMR spectra was recorded in deuterated water (D2O). The 'H chemical shifts were reported relative to internal D2O (FIG. 4). The 13 C NMR chemical shifts were reported relative to an external tetramethylsilane (TMS) standard (FIG. 8). NR’s proton and carbon NMR both showed a clean spectrum with no impurities.
- NMR nuclear magnetic resonance
- Mass Spectrometry A range of sophisticated mass spectrometric techniques had been utilized to develop a reliable quality control parameters for NR and its protein encapsulated products. Analysis of NR using electrospray ionization-mass spectrometry (ESI-MS) technique had been carried out. Apart from obtaining the elemental/isotopic signature of NR using MS, the [M+H]+ peak had been used for molecular weight estimation. The nicotinamide riboside anion [M] + peak of 255.09 was detected as the major peak (FIG. 10). The peak at 123.05 correlated to the nicotinamide [M+H] + fragment peak in NR.
- ESI-MS electrospray ionization-mass spectrometry
- Circular Dichroism (CD): NR was assessed by circular dichroism. The concentration of NR was 0.2 mg/ml in water. The circular Dichroism spectrum of NR was negative indicating S/L configuration (Fig.14). The anionic portion of NR might also introduce chirality.
- NR assessment Analysis of NR showed nicotinamide riboside containing compound. NMR showed a clean spectrum with no starting materials or solvent impurities. Mass spectrometric analysis showed peaks correlating to nicotinamide riboside and nicotinamide units. Circular Dichroism (CD) spectrum of NR was negative indicating S/L configuration.
- Quality Control Parameters Based on the research on quality control parameters for the Nicotinamide Riboside (NR), the above analytical tools were important for various NR- related product development through green nanotechnology-based NR encapsulations.
- CA was a fine white powder.
- Solubility CA was water soluble (25 mg/ml).
- pH CA displayed a pH of 7.0 in water indicating an neutral aqueous solution
- LC-MS Liquid chromatography-mass spectrometry
- CA assessment LC-MS analysis of CA showed pure material.
- CA is a well established compound and other elaborate characterization data can be obtained from National Institute of Standards and Technology (NIST) and Spectral Database for Organic Compounds (SDBS) websites.
- NIST National Institute of Standards and Technology
- SDBS Spectral Database for Organic Compounds
- TH was a fine white powder.
- Solubility CA was water soluble (25 mg/ml).
- TH assessment LC-MS analysis of TH showed pure material. TH is a well established compound and other elaborate characterization data can be obtained from National Institute of Standards and Technology (NIST) website.
- Water Soluble Pea Protein was purchased from WaterSolubleProtein.com website.
- the botanical source was Pisum sativum, natural and non-GMO yellow pea, which had been hydrolyzed to be highly water soluble (100 mg/ml).
- the protein solution was a clear yellow colored liquid with no sediments or residue. It had 80 % protein content. It was edible and instantly water soluble and forms stable solutions.
- Pea Protein UV-visible absorption spectroscopy The electronic transitions in water soluble Pea Protein (PP) pertains to the ultraviolet region (UV) based on the UV-visible absorption measurement. PP showed a weak absorption peak at 265 nm and a broad absorption in the 250 nm - 200 nm UV region (FIG. 17 A). There was no characteristic absorption peaks in the visible region.
- Pea Protein fluorescence spectroscopy Phenylalanine, tyrosine, and tryptophan amino acids in proteins gave rise to intrinsic protein fluorescence. The fluorescence emission spectra of water-soluble Pea Protein (PP) was recorded by excitation at 285 nm corresponding to the tryptophan amino acid.
- Pea Protein Matrix- Assisted Laser Desorption/Ionization-Mass Spectrometry (MALDI- MS): Water Soluble Pea Protein (PP) was analyzed using matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) to check the molecular weight of the protein components. Sinapic acid matrix was used. Mass range from 2kDa-400kDa was investigated on a Bruker AutoFlex Speed MALDI-MS and no significant peaks were seen. Then mass range was reduced to 5kDa, and peak around 877 and 993 m/z was seen indicating protein molecular weight below -IkDa (FIG. 18).
- FIG. 41 showed a 1H NMR of water-soluble Pea Protein (PP) in D2O.
- Soy protein isolate was obtained from MP Biomedicals, Catalog No. ICN90545605. Soy protein is an abundant and cheap plant protein obtained from soybean. Soy consumption is beneficial for heart health and reduces inflammation. Hence for diabetes, atherosclerosis and cancer treatment soy have significant applications. Soy Protein Isolate (SPI) is a soy food product with the maximum soy protein content (92%). SPI is water soluble and is a useful drug delivery vehicle for water soluble pharmaceuticals. SPI is considered generally safe pharmaceuticals, biodegradable cheap and abundantly available too. Soy protein’s antiinflammatory properties can also be harnessed in the nano- therapeutic formulation.
- Soy Protein Isolate UV-visible absorption spectroscopy The electronic transitions SPI pertains to the ultraviolet region (UV) based on the UV-visible absorption measurement. SPI showed a broad absorption in the 240 nm - 200 nm UV region (FIG. 42). There was no characteristic absorption peaks in the visible region.
- Soy Protein Isolate Matrix- Assisted Laser Desorption/Ionization-Mass Spectrometry (MALDI-MS): Water Soluble Pea Protein (PP) was analyzed using matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) to check the molecular weight of the protein components. Sinapic acid matrix was used. Mass range from 2kDa-400kDa was investigated on a Bruker AutoFlex Speed MALDI-MS. The significant peak was seen at 8960 m/z indicating protein molecular weight ⁇ 9 kDa (FIG. 34).
- Okra extract was obtained from Bulk Supplements, SKU OKR25kg.
- Okra is a flowering plant belonging in the mallow family. Its green seed pods are edible and consists of water (90%), protein (2%), carbohydrates (7%) and trace amounts of fat. It is a rich source of dietary fiber, vitamin C and vitamin K.
- Okra mucilage or gel from the pods is a natural polysaccharide and includes D-galactose, L-rhamnose and L-galacturonic acid. Okra mucilage be extracted in water and forms a gelatinous viscous solution. Natural polysaccharides are biocompatible, non-toxic, and have biogenic polymeric applications in the form of microspheres, nano-matrix and nanoparticles.
- Okra Extract a finely ground dry powder was purchased from BulkSupplements.com website. It was edible, water soluble and can be stored at room temperature. OE generated a faintly cloudy brown solution of okra mucilage or gel in water. Natural polysaccharides like okra gel could be used for encapsulation, stabilization and drug delivery applications.
- Okra mucilage Matrix- Assisted Laser Desorption/Ionization-Mass Spectrometry MALDI-MS: Okra mucilage or gel from the green seed pods was extracted in water. It was a gelatinous viscous solution. Okra mucilage was analyzed using matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) to check the molecular weight of the protein components. Sinapic acid matrix was used. Mass range from 2kDa-400kDa was investigated on a Bruker AutoFlex Speed MALDI-MS. A peak around ⁇ 8kDa was seen for the okra polysaccharide mucilage (FIG. 29).
- MALDI-MS matrix-assisted laser desorption/ionization-mass spectrometry
- Okra mucilage UV-visible absorption spectroscopy The electronic transitions in okra mucilage pertains mostly to the ultraviolet region (UV) based on the UV-visible absorption measurement. Okra Mucilage showed a weak broad absorption between 400 nm - 300 nm. Further in the UV region it showed a more intense broad absorption in the 300 nm - 200 region (FIG. 30). There was no characteristic absorption peaks in the visible region.
- FIG. 42 showed a 'H NMR of mangiferin in CD3OD.
- FIG. 45 showed a 'H NMR of epigallocatechin gallate (EGCG) in D2O.
- FIG. 48 showed a 'H NMR of quercetin in CD3OD.
- FIG. 51 showed a 'H NMR of resveratrol in CD3OD.
- GC-MS Gas chromatography-mass spectrometry
- chromatographic peaks in sample were deconvoluted using AMDIS and annotated through mass spectral and retention index matching to an in-house constructed spectral library and commercial NIST 17 mass spectral library. Neat KM standard with five different concentrations prepared in pyridine were similarly analyzed. Peak area was calculated using Agilent, Enhanced Data Analysis (EDA) software to generate a calibration curve. Using the calibration curve and the peak area of the GC peak of the sample solution at RT ⁇ 30 min, the concentration of the monoglycerides in KM solutions were accurately calculated.
- EDA Enhanced Data Analysis
- FIG. 43 showed a 1H NMR (expanded) of mangiferin and water-soluble Pea Protein (PP) reaction mixture in CD3OD/D2O (arrows indicate change in proton).
- FIG. 44 showed a NMR (expanded) of mangiferin, water soluble Pea Protein (PP) and KM reaction mixture in CD3OD/D2O.
- KM encapsulated Pea Protein Nanoparticles by Mango Peel crosslinking (KM-PP-MP- NP): Naturally available plant-based materials were explored for crosslinking. Mangiferin (MGF), a phytochemical found in mango, was extracted from the mango peel. The multiple hydroxyl groups in MGF were effective for protein crosslinking. KM encapsulated water-soluble Pea Protein Nanoparticles using Mango Peel crosslinking (KM-PP-MP-NP) was attempted by ethanol desolvation method (FIG. 15). After nanoparticle synthesis, any insoluble residue was removed by centrifugation/filtration.
- MGF Mangiferin
- FIG. 15 ethanol desolvation method
- KM-PP-MP-NP size was between 336-422 nm, with an average of 367 nm (using DLS) and showed an average zeta potential of -15 mV (Table 4) indicating reasonable stability.
- Poly dispersity index (PDI) of 0.2 indicates nanoparticles of uniform size (unimodal distribution).
- nanoparticle core size was explored by TEM (FIG. 23). It showed good particles with size in the -400 nm range.
- KM- PP-MP-NP was formulated and fully characterized to define quality control parameters for use in scale-up and commercial level productions.
- the particles showed an average size of 428 nm (using DLS) and an average zeta potential of -16 mV (Table 4), indicating reasonable stability.
- PDI of 0.2 indicated nanoparticles of uniform size (unimodal distribution).
- nanoparticle core size was explored by TEM (FIG. 19). It showed good particles with size in the -400 nm range. Blank nanoparticles were comparable to KM encapsulated nanoparticles with a slight increase in size. Blank Pea Protein Nanoparticles by Mango Peel crosslinking were synthesized with no KM for comparison (Serial No. 5).
- Table 4 Characterization of KM encapsulated Pea Protein Nanoparticles by ethanol desolvation method and Mango Peel crosslinking (KM-PP-MP-NP).
- KM-PP-MP-NP and PP-MP-NP fluorescence spectroscopy The fluorescence emission spectra of KM-PP-MP-NP and PP-MP-NP were recorded by excitation at 285 nm corresponding to the tryptophan amino acid. A broad emission peak at 351 nm with fluorescence intensity of 40 was seen in the emission spectra of (FIG. 21). Changes in the tryptophan microenvironment could be monitored through fluorescence spectroscopy. KM-PP-MP-NP and PP-MP-NP fluorescence maximum peak and intensity were comparable indicating not much change in the tryptophan region of the pea protein nanoparticles. Since KM was water soluble and hydrophilic, it did not interact with the hydrophobic tryptophan microenvironment of the pea protein. The fluorescence measurements gave insights into pea protein interaction with KM.
- GC-MS analysis of KM encapsulated Pea Protein Nanoparticles by Mango Peel crosslinking KM-PP-MP-NP: The amount of KM in the nanoparticle formulation was established using GC-MS analysis. It was found to be quantitative, indicating 100% KM encapsulation. A high KM encapsulation efficiency might be important for bio-delivery of KM.
- Extensive hydrogen bonding is a feature of KM, protein and phytochemical structures. This is not surprising considering the ester, hydroxyl, amine and oxo functional groups in their structures. Both intermolecular and intramolecular hydrogen bonding opportunities are extensive.
- NR-encapsulated pea protein nanoparticles by mango peel crosslinking 15 g of water-soluble pea protein (PP), 16 g mango peel (MP) powder, and 5 g nicotinamide riboside (NR) were weighed and transfer to a 2 L conical flask with a stir bar. 1 L distilled water was added to the flask, and the reaction mixture contents were stirred overnight. Mixing was stopped, and the insoluble residue was then allowed to settle. The insoluble residue was separated from the solution by decantation and then filtration (75-micron size). 700 mL of the filtered solution was transferred to a 2 L round bottom flask with a stir bar.
- PP water-soluble pea protein
- MP mango peel
- NR nicotinamide riboside
- NR-PP-MP-NP NR-encapsulated pea protein nanoparticles by mango peel crosslinking
- NR-encapsulated pea protein nanoparticles by mango peel crosslinking (NR-PP-MP-NP): Naturally available plant-based materials were explored for crosslinking. Mangiferin (MGF), a phytochemical found in mango, could be extracted from the mango peel. The multiple hydroxyl groups in MGF were effective for protein crosslinking.
- MGF Mangiferin
- NR-PP-MP-NP NR-encapsulated water- soluble pea protein nanoparticles using mango peel crosslinking
- FIG. 16 ethanol desolvation method
- NR-PP-MP-NP size was between 286-369 nm, with an average of 297 nm (using DLS) and showed an average zeta potential of -18 mV (Table 5a) indicating reasonable stability.
- Poly dispersity index (PDI) of 0.2 indicated nanoparticles of uniform size (unimodal distribution).
- nanoparticle core size was explored by TEM (FIG. 20). It showed particles with size in the -300 nm range.
- NP-PP-MP-NP was formulated and fully characterized to define quality control parameters for use in scale-up and commercial level productions. Blank nanoparticles were comparable to NR encapsulated nanoparticles with a slight increase in size.
- Table 5a Characterization of NR encapsulated Pea Protein Nanoparticles by ethanol desolvation method and Mango Peel crosslinking (NR-PP-MP-NP).
- NR-PP-MP-NP Mango Peel crosslinking
- Example 8b Crosslinking of pea protein with mangiferin and encapsulation of caffeine molecules in pea protein crosslinked with mangiferin
- CA-PP-MP-NP a product that was prepared by mango peel crosslinking
- 25 g of water-soluble pea protein (PP), 8 g mango peel (MP) powder, and 13 g caffeine (CA) were weighed and transferred to a 1 L conical flask with a stir bar.
- 500 mL distilled water was added to the flask, and the reaction mixture contents were stirred overnight. Then the reaction mixture was stirred overnight, and any insoluble residue was removed by centrifugation/filtration (75-micron size).
- CA-PP-MP-NP The resulting CA-encapsulated pea protein nanoparticles by mango peel crosslinking (CA-PP-MP-NP) were then characterized by TEM, DLS size and ZP measurements (Table 5b).
- the CA-PP-MP-NP solution was refrigerated (5°C ⁇ 3 °C) for extending shelf life.
- CA-encapsulated pea protein nanoparticles by mango peel crosslinking (CA-PP-MP-NP): Naturally available plant-based materials were explored for crosslinking. Mangiferin (MGF), a phytochemical found in mango, could be extracted from the mango peel. The multiple hydroxyl groups in MGF were effective for protein crosslinking.
- MGF Mangiferin
- CA-PP-MP-NP had an average size of 652 nm (using DLS) and showed an average zeta potential of -16 mV (Table 5b) indicating reasonable stability.
- Polydispersity index (PDI) of ⁇ 0.3 indicated nanoparticles of mostly uniform size (unimodal distribution).
- TEM TEM
- Table 5b Characterization of CA encapsulated Pea Protein Nanoparticles by Mango Peel crosslinking (CA-PP-MP-NP).
- a mango ped (MP) obtained from finely ground dried mango peei
- TH-encapsulated pea protein nanoparticles by mango peel crosslinking (TH- PP-MP-NP): 25 g of water-soluble pea protein (PP), 8 g mango peel (MP) powder, and 13 g theacrine (TH) were weighed and transferred to a 1 L conical flask with a stir bar. 500 mL distilled water was added to the flask, and the reaction mixture contents were stirred overnight. Then the reaction mixture was stirred overnight, and any insoluble residue was removed by centrifugation/filtration (75-micron size).
- TH-PP-MP-NP TH-encapsulated pea protein nanoparticles by mango peel crosslinking
- TH-encapsulated pea protein nanoparticles by mango peel crosslinking (TH-PP-MP-NP): Naturally available plant-based materials were explored for crosslinking. Mangiferin (MGF), a phytochemical found in mango, could be extracted from the mango peel. The multiple hydroxyl groups in MGF were effective for protein crosslinking. TH-PP-MP-NP had an average size of 563 nm (using DLS) and showed an average zeta potential of -17 mV (Table 5c) indicating reasonable stability. Polydispersity index (PDI) of ⁇ 0.5 indicated nanoparticles of slightly broad size distribution. Using negative staining technique, nanoparticle core size was explored by TEM (FIG. 20C). It showed particles with size in the -100 nm range. TH-PP-MP-NP was formulated and fully characterized to define quality control parameters for use in scale-up and commercial level productions.
- Table 5c Characterization of TH encapsulated Pea Protein Nanoparticles by Mango Peel crosslinking (TH-PP-MP-NP).
- TH-PP-MP-NP Mango Peel crosslinking
- KM encapsulated Pea Protein Nanoparticles were synthesized by Tea Extract crosslinking (KM-PP-TE-NP): Tea Extract (TE) solution was prepared for the nanoparticle synthesis. 6 g of Darjeeling loose-leaf tea (Table 3) was weighed and transferred to a 1 L conical flask. 300 mL distilled water was added to the flask, and the contents were boiled for 10 minutes at 100°C. The heating was then switched off and the tea extract solution was allowed to cool down to room temperature. The insoluble tea leaves residue from the solution were separated using Whatman paper filtration. The filtered, clear, deep-brown TE solution was utilized for the nanoparticle synthesis.
- Tea Extract (TE) solution was prepared for the nanoparticle synthesis. 6 g of Darjeeling loose-leaf tea (Table 3) was weighed and transferred to a 1 L conical flask. 300 mL distilled water was added to the flask, and the contents were boiled for 10 minutes at 100°C.
- KM-PP-TE-NP The resulting KM- encapsulated Pea Protein Nanoparticles by Tea Extract crosslinking (KM-PP-TE-NP) was then characterized by TEM, DLS size and ZP measurements. The KM content was estimated through GC-MS analysis and neat KM standard calibration described above. The KM-PP-TE-NP solution was refrigerated (5°C ⁇ 3°C) to extend the shelf life. Blank Pea Protein Nanoparticles by Tea Extract crosslinking (PP-TE-NP) were synthesized following the same procedure without addition of KM.
- FIG. 46 showed a NMR (expanded) of epigallocatechin gallate (EGCG) and water- soluble Pea Protein (PP) reaction mixture in D2O (arrows indicate change in proton).
- EGCG epigallocatechin gallate
- PP water- soluble Pea Protein
- FIG. 47 showed a NMR (expanded) of epigallocatechin gallate (EGCG), water soluble Pea Protein (PP) and KM reaction mixture in D2O.
- EGCG epigallocatechin gallate
- PP water soluble Pea Protein
- Tea leaves extract contain a variety of polyphenols including flavonoids, epigallocatechin gallate (EGCG) and other catechins.
- tea extract can be effective in crosslinking protein nanoparticles.
- KM-encapsulated water-soluble Pea Protein Nanoparticles using Tea Extract Crosslinking (KM-PP-TE-NP) was carried out by ethanol desolvation method. After nanoparticle synthesis, any insoluble residue was removed by centrifugation/filtration. Ethanol was removed from the formulation by rotatory evaporation at 37 degrees.
- KM-PP-TE- NP size was between 316-373 nm, with an average size of 338 nm (using DLS) and showed an average zeta potential of -13 mV (Table 6), indicating stability.
- Poly dispersity index (PDI) of ⁇ 0.2 indicates nanoparticles of uniform size (unimodal distribution).
- nanoparticle core size was estimated by TEM (FIG. 23). It showed stable particles with size in the -300 nm range.
- KM-PP-TE-NP was formulated and characterized to define quality control parameters for use in scale-up and commercial level productions. Initially small scale (-10 mL and 50 mL) nanoparticles were formulated. After establishing characterization and quality control parameters, it was scaled up to -1 L. KM from repeated batches were utilized for the large-scale synthesis. Large scale batches showed reliable scale-up and characterization parameters.
- GC-MS analysis of KM encapsulated Pea Protein Nanoparticles by Tea Extract crosslinking (KM-PP-TE-NP): The amount of KM in the nanoparticle formulation was established using GC-MS analysis. It was found to be quantitative indicating 100 % KM encapsulation. A high KM encapsulation efficiency may be important for bio-delivery of KM.
- the GC-MS column provided good resolution of the starting materials and various glycerides. Quantification of KM could be carried out by using pure and neat KM to obtain a calibration curve. The curve had good linearity and the analysis concentration fell within the calibration range. GC-MS can be used for quality control of the KM encapsulation process.
- Blank Protein Nanoparticles by Tea Extract crosslinking (PP-TE-NP): Blank Pea Protein Nanoparticles by Tea Extract crosslinking was synthesized with no KM for comparison. It showed a size of 362 nm (using DLS) and a zeta potential of -14 mV (Table 6) indicating reasonable stability. PDI of 0.1 indicates nanoparticles of uniform size (unimodal distribution). Using negative staining technique, nanoparticle core size was explored by TEM (FIG. 23). It showed good particles with size in the -400 nm range. Blank nanoparticles were comparable to KM encapsulated nanoparticles with a slight increase in size and potential.
- KM-PP-TE-NP and PP-TE-NP fluorescence spectroscopy The fluorescence emission spectra of KM-PP-TE-NP and PP-TE-NP were recorded by excitation at 285 nm corresponding to the tryptophan amino acid. A broad emission peak at 353 nm with fluorescence intensity of 30 was seen in the emission spectra of (FIG. 25). Changes in the tryptophan microenvironment could be monitored through fluorescence spectroscopy. KM-PP-TE-NP and PP-TE-NP fluorescence maximum peak and intensity were comparable indicating not much change in the tryptophan region of the pea protein nanoparticles. Since KM was water soluble and hydrophilic, it did not interact with the hydrophobic tryptophan microenvironment of the pea protein. The fluorescence measurements gave insights into pea protein interaction with KM.
- NR-encapsulated pea protein nanoparticles were synthesized by tea extract crosslinking (NR-PP-TE-NP): Tea Extract (TE) solution was prepared for the nanoparticle synthesis by weighing 5 g of Darjeeling loose-leaf tea and transferring it to a 1 L conical flask. 250 mL distilled water was added to the flask, and the contents were boiled for 10 minutes at 100°C. The heating was switched off, and the tea extract solution was allowed to cool down to room temperature. The insoluble tea leaves residue from the solution were separated using Whatman paper filtration. The filtered, clear, deep-brown TE solution was utilized for the nanoparticle synthesis.
- Tea Extract (TE) solution was prepared for the nanoparticle synthesis by weighing 5 g of Darjeeling loose-leaf tea and transferring it to a 1 L conical flask. 250 mL distilled water was added to the flask, and the contents were boiled for 10 minutes at 100°C. The heating was switched off,
- NR-PP-TE-NP NR-encapsulated Pea Protein Nanoparticles by Tea Extract crosslinking
- TEM TEM
- DLS size TEM
- ZP ZP
- the NR content was estimated through GC-MS analysis and neat KM standard calibration described above.
- the NR-PP-TE-NP solution was refrigerated (5°C ⁇ 3°C) to extend the shelf life.
- Blank Pea Protein Nanoparticles by Tea Extract crosslinking (PP-TE-NP) were synthesized following the same procedure without addition of NR.
- Tea leaves extract contain a variety of polyphenols like flavonoids, epigallocatechin gallate (EGCG), and other catechins.
- tea extract can be effective in crosslinking protein nanoparticles.
- NR-encapsulated water-soluble pea protein nanoparticles using tea extract crosslinking (NR-PP-TE-NP) was carried out by ethanol desolvation method. After nanoparticle synthesis, any insoluble residue that was larger than 75-micron in size was removed by centrifugation/filtration.
- NR-PP-TE-NP size was between 370-429 nm, with an average size of 415 nm (using DLS) and showed an average zeta potential of -14 mV (Table 7), indicating stability.
- PDI Poly dispersity index
- NR-PP-TE-NP was formulated and characterized to define quality control parameters for use in scale-up and commercial level productions. Initially small scale (-10 mL) nanoparticles were formulated. After establishing characterization and quality control parameters, it was scaled up to -1 L. NR from repeated batches were utilized for the large-scale synthesis. Large scale batches showed reliable scale-up and characterization parameters.
- Blank Protein Nanoparticles by Tea Extract crosslinking (PP-TE-NP): Blank Pea Protein Nanoparticles by Tea Extract crosslinking was synthesized with no NR for comparison. It showed a size of 370 nm (using DLS) and a zeta potential of -19 mV (Table 7a) indicating reasonable stability. PDI of 0.1 indicates nanoparticles of uniform size (unimodal distribution). Using negative staining technique, nanoparticle core size was explored by TEM (FIG. 16). It showed good particles with size in the -300 nm range. Blank nanoparticles were comparable to NR encapsulated nanoparticles with a slight increase in size and potential.
- CA-encapsulated pea protein nanoparticles were synthesized by tea extract crosslinking (CA-PP-TE-NP): Tea Extract (TE) solution was prepared for the nanoparticle synthesis by weighing 5 g of Darjeeling loose-leaf tea and transferring it to a 1 L conical flask. 250 mL distilled water was added to the flask, and the contents were boiled for 10 minutes at 100°C. The heating was switched off, and the tea extract solution was allowed to cool down to room temperature. The insoluble tea leaves residue from the solution were separated using Whatman paper filtration. The filtered, clear, deep-brown TE solution was utilized for the nanoparticle synthesis.
- Tea Extract (TE) solution was prepared for the nanoparticle synthesis by weighing 5 g of Darjeeling loose-leaf tea and transferring it to a 1 L conical flask. 250 mL distilled water was added to the flask, and the contents were boiled for 10 minutes at 100°C. The heating was switched off, and
- Tea leaves extract contain a variety of polyphenols like flavonoids, epigallocatechin gallate (EGCG), and other catechins.
- tea extract can be effective in crosslinking protein nanoparticles.
- CA-encapsulated water-soluble pea protein nanoparticles using tea extract crosslinking (CA-PP-TE-NP) was carried out. After nanoparticle synthesis, any insoluble residue that was larger than 75-micron in size was removed by centrifugation/filtration.
- CA-PP-TE-NP had an average size of 330 nm (using DLS) and a zeta potential of -13 mV (Table 7b).
- nanoparticle core size was estimated by TEM (FIG. 24B). It showed longitudinal particles with size in the -500 nm range.
- CA-PP-TE-NP was formulated and characterized to define quality control parameters for use in scale-up and commercial level productions. Initially small scale ( ⁇ 10 mL) nanoparticles were formulated.
- TH-encapsulated pea protein nanoparticles were synthesized by tea extract crosslinking (TH-PP-TE-NP): Tea Extract (TE) solution was prepared for the nanoparticle synthesis by weighing 5 g of Darjeeling loose-leaf tea and transferring it to a 1 L conical flask. 250 mL distilled water was added to the flask, and the contents were boiled for 10 minutes at 100°C. The heating was switched off, and the tea extract solution was allowed to cool down to room temperature. The insoluble tea leaves residue from the solution were separated using Whatman paper filtration. The filtered, clear, deep-brown TE solution was utilized for the nanoparticle synthesis.
- Tea Extract (TE) solution was prepared for the nanoparticle synthesis by weighing 5 g of Darjeeling loose-leaf tea and transferring it to a 1 L conical flask. 250 mL distilled water was added to the flask, and the contents were boiled for 10 minutes at 100°C. The heating was switched off,
- TH-PP-TE-NP TH-encapsulated Pea Protein Nanoparticles by Tea Extract crosslinking
- Tea leaves extract contain a variety of polyphenols like flavonoids, epigallocatechin gallate (EGCG), and other catechins.
- tea extract can be effective in crosslinking protein nanoparticles.
- TH-encapsulated water-soluble pea protein nanoparticles using tea extract crosslinking (TH-PP-TE-NP) was carried out. After nanoparticle synthesis, any insoluble residue that was larger than 75-micron in size was removed by centrifugation/filtration.
- TH-PP-TE-NP had an average size of 322 nm (using DLS) and a zeta potential of -12 mV (Table 7c).
- nanoparticle core size was estimated by TEM (FIG. 24C). It showed particles with size in the -100 nm range.
- TH-PP-TE-NP was formulated and characterized to define quality control parameters for use in scale-up and commercial level productions. Initially small scale (-50 mL) nanoparticles were formulated. After establishing characterization and quality control parameters, it was scaled up to -500 mL. Large scale batches showed reliable scale-up and characterization parameters.
- the filtered clear purple BE aqueous solution was used. 50.0 g water soluble Pea Protein (PP) and 300.0 g Ketone Molecule (KM) were weighed and transferred to a 2 L conical flask with a stir bar. 1000 mL of the BE extract aqueous solution were added to the flask, and the contents were boiled for 15 minutes at 100°C. Then, while stirring, 333 mL of absolute ethanol was added to the flask, and the reaction mixture contents were stirred overnight. The resulting KM encapsulated Pea Protein Nanoparticles by Berry Extract crosslinking (KM-PP-BE-NP) were characterized by TEM, DLS size and ZP measurements. The KM-PP-BE-NP solution was refrigerated (5 ⁇ 3 °C) for extending shelf life. Blank Pea Protein Nanoparticles by Berry Extract crosslinking (PP-BE-NP) was synthesized following the same procedure without addition of KM.
- PP-PP-NP Ketone Molecule
- the quercetin proton NMR showed equivalent peaks at 7.7, 7.6, 6.9, 6.4 and 6.2 ppm. After reaction with the pea protein, the doublet peak at 6.4 ppm decreased significantly (FIGS. 48 and 49). NMR analysis clearly showed distinct change in quercetin indicating covalent interaction with the protein opening crosslinking pathways. The aromatic ring protons of the phytochemical showed distinct changes indicating covalent interaction with the protein. These changes led to crosslinking with protein amino functional groups.
- the quercetin proton NMR showed equivalent peaks at 7.7, 7.6, 6.9, 6.4 and 6.2 ppm. But after reaction with the pea protein, the doublet peak at 6.4 ppm decreased significantly.
- the black berry extract containing the quercetin was a phytochemical cocktail containing various other active ingredients which can also play a role in the crosslinking and encapsulation process whilst adding nutraceutical value to the formulation.
- FIG. 49 showed a 1H NMR (expanded) of quercetin and water-soluble Pea Protein (PP) reaction mixture in CD3OD/D2O (arrows indicate change in proton).
- FIG. 50 showed a NMR (expanded) of quercetin, water soluble Pea Protein (PP) and KM reaction mixture in CD3OD/D2O.
- TEM was used to investigate the size of nanoparticles using the negative staining technique nanoparticle (FIG. 27A). It showed a particle size in the range -100-500 nm.
- KM-PP-BE-NP was formulated and fully characterized to define quality control parameters for scale-up and commercial manufacturing. Initially, nanoparticles on a small scale (-10 mL) were formulated. After establishing characterization and quality control parameters, it was successfully scaled up to -1 L to test large scale production. Large scale batches demonstrated reproducible scaling-up and characterization parameters. These experiments had aided in the definition of quality control parameters for usage at scale-up and commercial level productions.
- Table 8a Characterization of KM encapsulated Pea Protein Nanoparticles by ethanol desolvation method and Berry extract crosslinking (KM-PP-BE-NP).
- a Bens? pondered istract (25 usg/mL) boiled at too degrees
- b Berry extract (50 Esg/us ) bailed at toe degrees
- CA-PP-BE-NP aqueous solution of Blackberry Extract (BE) for the nanoparticle synthesis was prepared. 25 g of dried purple berry powder was weighed and transferred to a 1 L conical flask. 500 ml distilled water was added to the flask, and the contents were allowed boil for 15 minutes at 100°C. Then the heat was turned off, and the solution was allowed to cool down to room temperature, allowing any remaining insoluble berry fruit powder residues to settle down. The insoluble residues from the purple solution were separated by decantation and then filtration (use a strainer of 75-micron mesh or carry out centrifugation).
- the filtered clear purple BE aqueous solution was used for the nanoparticle synthesis.
- 25 g water soluble Pea Protein (PP) and 13 g caffeine (CA) were weighed and transferred to a 1 L conical flask with a stir bar.
- 250 mL of the BE extract aqueous solution and 250 mL distilled water were added to the flask, and the mixture stirred overnight.
- the resulting CA encapsulated Pea Protein Nanoparticles by Berry Extract crosslinking (CA-PP-BE-NP) were characterized by TEM, DLS size and ZP measurements.
- the CA-PP-BE-NP solution was refrigerated (5 ⁇ 3 °C) for extending shelf life.
- TEM was used to investigate the size of nanoparticles using the negative staining technique nanoparticle (FIG. 27C). It showed a particle size in the range -200 nm.
- CA-PP-BE-NP was formulated and fully characterized to define quality control parameters for scale-up and commercial manufacturing. Initially, nanoparticles on a small scale ( ⁇ 10 mL) were formulated. After establishing characterization and quality control parameters, it was successfully scaled up to -500 mL to test large scale production. Large scale batches demonstrated reproducible scaling-up and characterization parameters. These experiments had aided in the definition of quality control parameters for usage at scale-up and commercial level productions.
- Table 8b Characterization of CA encapsulated Pea Protein Nanoparticles by Berry extract crosslinking (CA-PP-BE-NP).
- CA-PP-BE-NP Berry extract crosslinking
- a Berry powder (50 mg/mt) boiled at 100 degrees for berry extract (BE)
- TH-PP-BE-NP aqueous solution of Blackberry Extract (BE) for the nanoparticle synthesis was prepared. 25 g of dried purple berry powder was weighed and transferred to a 1 L conical flask. 500 ml distilled water was added to the flask, and the contents were allowed boil for 15 minutes at 100°C. Then the heat was turned off, and the solution was allowed to cool down to room temperature, allowing any remaining insoluble berry fruit powder residues to settle down. The insoluble residues from the purple solution were separated by decantation and then filtration (use a strainer of 75-micron mesh or carry out centrifugation).
- the filtered clear purple BE aqueous solution was used for the nanoparticle synthesis.
- 25 g water soluble Pea Protein (PP) and 13 g theacrine (TH) were weighed and transferred to a 1 L conical flask with a stir bar.
- 230 mL of the BE extract aqueous solution and 230 mL distilled water were added to the flask, and the mixture stirred overnight.
- the resulting TH encapsulated Pea Protein Nanoparticles by Berry Extract crosslinking (TH-PP-BE-NP) were characterized by TEM, DLS size and ZP measurements.
- the TH-PP-BE-NP solution was refrigerated (5 ⁇ 3°C) for extending shelf life.
- TEM was used to investigate the size of nanoparticles using the negative staining technique nanoparticle (FIG. 27D). It showed a particle size in the range -100 nm.
- TH-PP-BE-NP was formulated and fully characterized to define quality control parameters for scale-up and commercial manufacturing. Initially, nanoparticles on a small scale (-10 mL) were formulated. After establishing characterization and quality control parameters, it was successfully scaled up to -500 mL to test large scale production. Large scale batches demonstrated reproducible scaling- up and characterization parameters. These experiments had aided in the definition of quality control parameters for usage at scale-up and commercial level productions.
- Table 8c Characterization of TH encapsulated Pea Protein Nanoparticles by Berry extract crosslinking (TH-PP-BE-NP).
- TH-PP-BE-NP Berry extract crosslinking
- a Berry powder (50 mg/mt) boiled at 100 degrees for berry extract (BE)
- Example 16 Crosslinking of pea protein with resveratrol and Encapsulation of ketone molecules in pea protein crosslinked with resveratrol
- FIG. 52 showed a 'H NMR (expanded) of resveratrol and water-soluble Pea Protein (PP) reaction mixture in CD3OD/D2O (arrows indicate change in proton).
- FIG. 53 showed a X H NMR (expanded) of resveratrol, water soluble Pea Protein (PP) and KM reaction mixture in CD3OD/D2O.
- Resveratrol was a well know antioxidant, with electroactive hydroxy groups facilitated by a planar structure due to the double bond. Also, the grape extract containing the resveratrol was a phytochemical cocktail containing various other active ingredients which can also play a role in the crosslinking and encapsulation process whilst adding nutraceutical value to the formulation.
- the framework of Grape Extract was investigated for nano-encapsulation of KM.
- Grape extract contains flavonoids and resveratrol, among other polyphenols.
- the KM encapsulated Pea protein grape extract crosslinked nanoparticles (KM-PP-GE-NP) were produced by combining an aqueous solution of GE, Pea protein, and KM stirring overnight. KM was absorbed or incorporated into the grape framework, which forms a nano-matrix.
- the size of KM-PP-GE-NP was between 499-607 nm, with an average size of 553 nm (using DLS) and the average zeta potential was determined to be -10 mV (Table 9), showing reasonable stability.
- TEM was used to investigate the size and morphology of nanoparticles using negative staining technique (FIG. 27B). It showed good particle size in the range -200-600 nm.
- KM-PP-GE-NP was formulated and completely characterized to establish quality control criteria for scale-up and commercial productions. Initially, small scale ( ⁇ 10 mL) nanoparticles were formulated, thereafter production was scaled-u to ⁇ 1 L after establishing characterization and quality control parameters. For the large-scale synthesis, KM from several batches was utilized for the large-scale synthesis. Large scale batches demonstrated reliable scaling up and characterization parameters.
- Soy Protein Isolate (SPI) framework was explored for nano-encapsulation of KM by desolvation method. Since soy protein was explored at the very beginning, glutaraldehyde was used for crosslinking to check for nanoparticle formation before utilizing plant-based phytochemicals. But mango peel, tea, berry, and grape extracts can also be used for crosslinking the nanoparticles.
- KM loaded Soy Protein Isolate Nanoparticles (KM-SPI-NP) was prepared by ethanol desolvation method. KM-SPI-NPs were formulated and fully characterized to define quality control parameters for use in scale-up and commercial level productions.
- KM-SPI-NP size was between 151-230 nm (using DLS).
- TEM TEM
- Example 18 Encapsulation of ketone molecules in okra extract crosslinked with okra extract.
- KM-OE-NP KM encapsulated Okra Extract Nanoparticles
- 10 g Okra Extract (OE) powder and 25 g Ketone Molecule (KM) were weighed and transferred to a 1 L conical flask with a stir bar.
- 500 mL distilled water was added to the flask and the contents were stirred for an hour.
- 2 g ascorbic acid, a preservative was weighed and transfer to the flask and stirred overnight.
- the resulting KM encapsulated Okra Extract (KM-OE-NP) was characterized by TEM, DLS size and ZP measurements.
- the KM content was estimated through GC-MS analysis and neat KM standard calibration.
- the KM-OE-NP solution was refrigerated (5°C ⁇ 3°C) for extending shelf life. Blank Okra Extract (OE) without addition of KM was utilized for comparison with KM-OE-NP.
- Okra Extract (OE) framework was explored for nano-encapsulation of KM.
- OE Okra Extract
- KM-OE-NP size was 158 nm (using DLS) and showed a zeta potential of -22 mV (Table 11) indicating reasonable stability.
- Poly dispersity index (PDI) of 0.6 indicates nanoparticles of not very uniform size (away from unimodal distribution). Losing negative staining technique nanoparticle core size was explored by TEM (FIG. 31).
- KM-OE-NP was formulated and fully characterized to define quality control parameters for use in scale-up and commercial level productions. Initially small scale (-10 mL) nanoparticles were formulated. After establishing characterization and quality control parameters it was scaled up to -1 L. KM from various batches were utilized for the large-scale synthesis. Ascorbic acid was added as a preservative as well. Therefore, there was a change in the size and zeta potential. The size was 280 nm (using DLS) and showed a zeta potential of -9 mV (Table 11). Large scale batches showed reliable scale-up and characterization parameters. These experiments had helped to define quality control parameters for use in scale-up and commercial level productions.
- Blank Okra Extract Blank aqueous okra extract with no KM was also characterized for comparison. It showed a size of 82 nm (using DLS) and a zeta potential of -27 mV (Table 11) indicating good stability. PDI of 1.0 indicated an okra gel nano-matrix of non-uniform size (multimodal distribution). Using negative staining technique okra extract core size was explored by TEM (FIG. 31). It showed sparse particles with size in the -100 nm range. KM encapsulated Okra Extract Nanoparticles (KM-OE-NP) showed more particles with better polydispersity value in comparison to blank okra extract.
- GC-MS analysis of KM encapsulated Okra Extract Nanoparticles (KM-OE-NP): The amount of KM in the nanoparticle formulation was established using GC-MS analysis. It was found to be quantitative indicating 100 % KM encapsulation. A high KM encapsulation efficiency may be important for bio-delivery of KM.
- the GC-MS column provided good resolution of the starting materials and various glycerides. Quantification of KM can be carried out by using the glyceryl tributyrate (GTB) standard and obtaining a calibration curve. The curve should have good linearity and the analysis concentration should fall within the calibration range.
- GTB glyceryl tributyrate
- the curve should have good linearity and the analysis concentration should fall within the calibration range.
- GC-MS can be used for quality control of the KM encapsulation process.
- Example 20 Encapsulation of NR molecules in okra extract crosslinked with okra extract.
- NR-encapsulated okra extract nanoparticles 10 g Okra Extract (OE) powder (Table 3) and 25 g NR were weighed and transferred to a 1 L conical flask with a stir bar. 500 mL distilled water was added to the flask and the contents were stirred for an hour. 2 g ascorbic acid, a preservative, was weighed and transferred to the flask and stirred overnight.
- the resulting NR encapsulated Okra Extract (NR-OE-NP) was characterized by TEM, DLS size, and ZP measurements.
- the NR-OE-NP solution was refrigerated (5°C ⁇ 3°C) for extending shelf life. Blank Okra Extract (OE) without addition of NR was utilized for comparison with NR-OE-NP.
- Okra Extract (OE) framework was explored for nano-encapsulation of NR.
- OE Okra Extract
- NR-OE-NP size was 149 nm (using DLS) and showed a zeta potential of -17 mV (Table 12) indicating reasonable stability.
- Poly dispersity index (PDI) of 0.5 indicated nanoparticles of not very uniform size (away from unimodal distribution).
- TEM TEM
- NR-OE-NP was formulated and fully characterized to define quality control parameters for use in scale-up and commercial level productions. Initially small scale (-10 mL) nanoparticles were formulated. After establishing characterization and quality control parameters it was scaled up to -1 L. NR from various batches were utilized for the large-scale synthesis. Ascorbic acid was added as a preservative as well. However, there was not much change in the size and zeta potential. The size was 162 nm (using DLS) and showed a zeta potential of -9 mV (Table 8). Large scale batches showed reliable scale-up and characterization parameters. These experiments had helped to define quality control parameters for use in scale-up and commercial level productions.
- Blank Okra Extract Blank aqueous okra extract with no NR was also characterized for comparison. It showed a size of 82 nm (using DLS) and a zeta potential of -27 mV (Table 12) indicating good stability. PDI of 1.0 indicated an okra gel nano-matrix of non-uniform size (multimodal distribution). Using negative staining technique okra extract core size was explored by TEM (FIG. 32). It showed sparse particles with size in the -100 nm range. NR encapsulated Okra Extract Nanoparticles (NR-OE-NP) showed more particles with better poly dispersity value in comparison to blank okra extract. [0335] Table 12: Characterization of NR Okra Gel Nanoparticles (NR-OE-NP)
- Example 21 Folin-Ciocalteu analysis for total phenols of KM encapsulated pea protein nanoparticles by plant-based (Mango peel, tea, berry, and grape extracts) crosslinking
- Total phenolic content can be an important component of beverages, supplements, functional foods, food additives, and nutraceutical industries, providing flavor, color, and sensory qualities such as bitterness and astringency, scent, and haze development during storage. Phenols can exhibit antioxidant activity due to their extensive, conjugated 7t-electron systems which facilitate the donation of electrons or hydrogen atoms to free radicals from the hydroxyl moieties.
- the oxygen radical absorbance capacity (ORAC) of whole foods, juices, and food additives was previously utilized as the industry standard for determining the antioxidant strength of these foods.
- the ORAC method made use of the peroxyl radical, the most abundant free radical found in the human body.
- the energy-enhancing KM within the nanoencapsulation platform contains a number of health-promoting constituents, including antioxidant polyphenols from mango peel, tea, berry, and grape extracts.
- Antioxidant-rich products are important because they protect body’s cells from the destructive effects of free radicals which can damage proteins, lipids, and DNA, thereby reducing and preventing the development of various degenerative diseases such as cancer and coronary heart disease.
- Phenols provide health benefits through several mechanisms, including the elimination of free radicals and the protection and regeneration of other dietary antioxidants (e.g., vitamin E) acting as protective, and valuable group of phytoconstituents due to their high antioxidant activity and healing properties.
- the total phenol content was determined using the Folin-Ciocalteu method, which involved reducing the Folin-Ciocalteu reagent with the polyphenols present in nanoformulation.
- the total phenol content was quantified using total gallic acid equivalents (GAE), the most frequently used reference molecule.
- GAE total gallic acid equivalents
- Total phenol content was 236 mg GAE/g for KM-PP-MP-NP, 127 mg GAE/g for KM-PP-TE-NP, 205 mg GAE/g for KM-OE-NP, 324 mg GAE/g for KM-PP-BE-NP, 275 mg GAE/g for KM-PP-GE-NP, and 12 mg GAE/g for KM- PP-NPs as shown in FIG. 28.
- Example 22 Cellular assay toxicity studies for KM and KM encapsulated Pea Protein Nanoparticles by Tea Extract crosslinking (KM-PP-TE-NP)
- HAEC human aortic endothelial cells
- the cell proliferation assay kit used 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT), a tetrazolium dye for measurement of the cell viability.
- MTT 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide
- Using the MTT assay cell viability was measured for both KM and KM-encapsulated nanoparticles.
- HAEC after 24, 48 and 72 hours (hr) post incubation with KM showed no toxicity over the concentration range 81-1300 pg/mL.
- FIG. 26A KM-encapsulated pea protein isolate nanoparticles cross-linked with tea extract (KM-PP-TE-NP) was also synthesized. HAEC after 24, 48 and 72 hr post incubation with KM-PPI-NP showed no toxicity over the concentration range 81-650 pg/mL. This was shown in FIG. 26B. Compared to the free KM, the toxicity concentration for KM encapsulated nanoparticles was slightly lower. This observation inferred enhanced bioavailability of KM in KM-PP-TE-NP. KM concentration in KM-PP-MP-NP was used for plotting the concentration values.
- KM-PP-MP-NP human aortic endothelial cells
- the cell proliferation assay kit used 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT), a tetrazolium dye for measurement of the cell viability.
- MTT 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide
- MTT 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide
- FIG. 22A KM encapsulated pea protein isolate nanoparticles cross-linked with mango peel (KM-PP-MP-NP) was also synthesized. HAEC after 24, 48 and 72 hr post incubation with KM-PPI-NP showed no toxicity over the concentration range 9-71 pg/mL. This was shown in FIG. 22B. Compared to the free KM, the toxicity concentration for KM-encapsulated nanoparticles was slightly lower. This observation inferred enhanced bioavailability of KM in KM-PP-MP-NP. KM concentration in KM-PP-MP-NP was used for plotting the concentration values.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202380049897.4A CN119730732A (en) | 2022-05-11 | 2023-05-09 | Systems and methods for small molecule encapsulation |
| CA3252814A CA3252814A1 (en) | 2022-05-11 | 2023-05-09 | Systems and methods for small molecule encapsulation |
| JP2024566559A JP2025517684A (en) | 2022-05-11 | 2023-05-09 | Systems and methods for small molecule encapsulation |
| AU2023267573A AU2023267573A1 (en) | 2022-05-11 | 2023-05-09 | Systems and methods for small molecule encapsulation |
| EP23804150.3A EP4521958A4 (en) | 2022-05-11 | 2023-05-09 | SYSTEMS AND METHODS FOR ENCAPSULING SMALL MOLECULES |
| KR1020247040504A KR20250008102A (en) | 2022-05-11 | 2023-05-09 | Systems and methods for small molecule encapsulation |
| US18/942,098 US20250205162A1 (en) | 2022-05-11 | 2024-11-08 | Systems and methods for small molecule encapsulation |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340820P | 2022-05-11 | 2022-05-11 | |
| US63/340,820 | 2022-05-11 | ||
| US202363453958P | 2023-03-22 | 2023-03-22 | |
| US63/453,958 | 2023-03-22 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US18/942,098 Continuation US20250205162A1 (en) | 2022-05-11 | 2024-11-08 | Systems and methods for small molecule encapsulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023220081A1 true WO2023220081A1 (en) | 2023-11-16 |
Family
ID=88730908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/021578 Ceased WO2023220081A1 (en) | 2022-05-11 | 2023-05-09 | Systems and methods for small molecule encapsulation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250205162A1 (en) |
| EP (1) | EP4521958A4 (en) |
| JP (1) | JP2025517684A (en) |
| KR (1) | KR20250008102A (en) |
| CN (1) | CN119730732A (en) |
| AU (1) | AU2023267573A1 (en) |
| CA (1) | CA3252814A1 (en) |
| WO (1) | WO2023220081A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118436011A (en) * | 2024-07-08 | 2024-08-06 | 妙事达茶业(云南)有限公司 | A kind of preparation method of novel instant tea |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020104970A2 (en) * | 2018-11-20 | 2020-05-28 | Sphera Encapsulation Srl | Multi-layered particles |
| US20200268778A1 (en) * | 2019-02-21 | 2020-08-27 | ChromaDex Inc. | Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations |
| WO2020229670A1 (en) * | 2019-05-16 | 2020-11-19 | Chr. Hansen A/S | Methods for encapsulation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230025435A1 (en) * | 2020-01-06 | 2023-01-26 | Juvn3 Holdings, Llc | Compositions and methods for increasing cellular vitality and longevity and decreasing molecular ageing |
-
2023
- 2023-05-09 KR KR1020247040504A patent/KR20250008102A/en active Pending
- 2023-05-09 AU AU2023267573A patent/AU2023267573A1/en active Pending
- 2023-05-09 EP EP23804150.3A patent/EP4521958A4/en active Pending
- 2023-05-09 CN CN202380049897.4A patent/CN119730732A/en active Pending
- 2023-05-09 CA CA3252814A patent/CA3252814A1/en active Pending
- 2023-05-09 JP JP2024566559A patent/JP2025517684A/en active Pending
- 2023-05-09 WO PCT/US2023/021578 patent/WO2023220081A1/en not_active Ceased
-
2024
- 2024-11-08 US US18/942,098 patent/US20250205162A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020104970A2 (en) * | 2018-11-20 | 2020-05-28 | Sphera Encapsulation Srl | Multi-layered particles |
| US20200268778A1 (en) * | 2019-02-21 | 2020-08-27 | ChromaDex Inc. | Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations |
| WO2020229670A1 (en) * | 2019-05-16 | 2020-11-19 | Chr. Hansen A/S | Methods for encapsulation |
Non-Patent Citations (5)
| Title |
|---|
| CUEVAS-BERNARDINO JUAN C., LEYVA-GUTIERREZ FRANCISCO M.A., VERNON-CARTER E. JAIME, LOBATO-CALLEROS CONSUELO, ROMÁN-GUERRERO ANGÉLI: "Formation of biopolymer complexes composed of pea protein and mesquite gum – Impact of quercetin addition on their physical and chemical stability", FOOD HYDROCOLLOIDS, ELSEVIER BV, NL, vol. 77, 1 April 2018 (2018-04-01), NL , pages 736 - 745, XP093113423, ISSN: 0268-005X, DOI: 10.1016/j.foodhyd.2017.11.015 * |
| FAN YUTING; ZENG XIANXIE; YI JIANG; ZHANG YUZHU: "Fabrication of pea protein nanoparticles with calcium-induced cross-linking for the stabilization and delivery of antioxidative resveratrol", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 152, 24 February 2020 (2020-02-24), NL , pages 189 - 198, XP086148295, ISSN: 0141-8130, DOI: 10.1016/j.ijbiomac.2020.02.248 * |
| GÜZEL NIHAL, KAHRAMAN OZAN, FENG HAO: "Solid–Liquid Extraction by Manothermosonication: Recapturing the Value of Pomegranate Peels and Nanocomplexation of Extracts with Pea Protein", ACS SUSTAINABLE CHEMISTRY & ENGINEERING, AMERICAN CHEMICAL SOCIETY, US, vol. 8, no. 44, 9 November 2020 (2020-11-09), US , pages 16671 - 16679, XP093113425, ISSN: 2168-0485, DOI: 10.1021/acssuschemeng.0c06316 * |
| LI JUMING, CHEN ZHONG: "Fabrication of heat-treated soybean protein isolate-EGCG complex nanoparticle as a functional carrier for curcumin", LWT- FOOD SCIENCE AND TECHNOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 159, no. 113059, 1 April 2022 (2022-04-01), United Kingdom , XP093113422, ISSN: 0023-6438, DOI: 10.1016/j.lwt.2021.113059 * |
| See also references of EP4521958A4 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118436011A (en) * | 2024-07-08 | 2024-08-06 | 妙事达茶业(云南)有限公司 | A kind of preparation method of novel instant tea |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023267573A1 (en) | 2024-11-21 |
| JP2025517684A (en) | 2025-06-10 |
| KR20250008102A (en) | 2025-01-14 |
| CA3252814A1 (en) | 2023-11-16 |
| CN119730732A (en) | 2025-03-28 |
| EP4521958A4 (en) | 2026-04-22 |
| US20250205162A1 (en) | 2025-06-26 |
| EP4521958A1 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghanbarzadeh et al. | Nano-phytosome as a potential food-grade delivery system | |
| Pettinato et al. | Bioactives extraction from spent coffee grounds and liposome encapsulation by a combination of green technologies | |
| Thakur et al. | Microencapsulation of wild pomegranate flavedo phenolics by lyophilization: Effect of maltodextrin concentration, structural morphology, functional properties, elemental composition and ingredient for development of functional beverage | |
| Kim et al. | Free and bound form bioactive compound profiles in germinated black soybean (Glycine max L.) | |
| JP2017509316A (en) | Stabilized blue phycocyanin | |
| Mel et al. | Formulation of microencapsulated rutin and evaluation of bioactivity and stability upon in vitro digestive and dialysis conditions | |
| He et al. | Phytochemicals, nutritionals and antioxidant properties of miracle fruit Synsepalum dulcificum | |
| US10912737B2 (en) | Nano complex comprising a nano drug delivery matrix; and a ginseng extract or a ginsenoside isolated therefrom | |
| Grassia et al. | Chemical composition and microencapsulation suitability of sumac (Rhus coriaria L.) fruit extract | |
| US20250205162A1 (en) | Systems and methods for small molecule encapsulation | |
| Vifta et al. | Nanoparticle from Medinilla speciosa with various of encapsulating agent and their antioxidant activities using ferric reducing assay | |
| Hădărugă et al. | Hydroxycinnamic acids | |
| KR20130121385A (en) | A granule improved stock stability of anthocyanin pigment from mulberry, blueberry and s. chinensis baillon extracts and manufacturing method of the same | |
| Srihanam et al. | Phytochemicals and antioxidant activity in sugarcane (Saccharum officinarum L.) bagasse extracts | |
| US9173916B2 (en) | Method of preparing a muscadine pomace extract | |
| KR101601237B1 (en) | A granule improved stock stability of anthocyanin pigment from Mulberry, Blueberry and S. chinensis Baillon extracts and manufacturing method of the same | |
| JP6445518B2 (en) | Method for preparing muscadine impomas extract | |
| EP3758512A1 (en) | Nanoparticles of cocoa extract and use thereof as antioxidants | |
| EP4501340A1 (en) | Method for producing ellagic acid-containing composition and ellagic acid-containing composition | |
| Maryam | Total phenol, flavonoid levels and IC50 in local grape (Vitis vinifera L) skin waste wine | |
| R Maghraby | Nanoencapsulation of Jania rubens’ Phytochemicals: Antioxidant Properties for Food Applications | |
| Fiadorwu | Multipronged Approach to Profiling Metabolites in the Extract of Beetroot (Beta vulgaris L.) Dried Pulp Using Chromatography, NMR, and Other Spectroscopy Methods; and Separate the Metabolites Using Nanoparticles | |
| Rubio | Utilization of brewer\'s spent yeast as a bio-vehicle for incorporation and protection of bioactive compounds | |
| Mesbah et al. | Extraction of Morinda Citrifolia by Subcritical Water: Effect of Temperature on Antioxidant and Total Phenolic Activity. | |
| Taghinia et al. | Encapsulation of stevia extract in lignin nanoparticle: A strategy to facilitate its use in active packaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23804150 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: AU2023267573 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024566559 Country of ref document: JP |
|
| ENP | Entry into the national phase |
Ref document number: 2023267573 Country of ref document: AU Date of ref document: 20230509 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11202407665T Country of ref document: SG |
|
| ENP | Entry into the national phase |
Ref document number: 20247040504 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202417096149 Country of ref document: IN Ref document number: 1020247040504 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023804150 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2023804150 Country of ref document: EP Effective date: 20241211 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202380049897.4 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 202380049897.4 Country of ref document: CN |



































